

Curriculum Vitae and Bibliography

Walter R Wilson, MD

Personal Information

Place of Birth: Del Rio, TX
Citizenship: United States of America
Work Address: Mayo Clinic Rochester
200 First St SW
Rochester, MN 55905-0001
Email Address: wilson.walter@mayo.edu

Present Academic Rank and Position

Consultant - Division of Infectious Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 07/1975 - Present

Professor of Medicine - Mayo Clinic College of Medicine and Science 07/1984 - Present

Consultant (Joint Appointment) - Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota 02/1995 - Present

Education

Baylor University - BA, Chemistry 1959 - 1963

Baylor College of Medicine - MD, Medicine 1963 - 1967

Methodist Hospital, Houston, TX - Internship, General Medicine 1967 - 1968

Mayo Graduate School of Medicine, Mayo Clinic College of Medicine - Resident, Internal Medicine 1972 - 1973

Mayo Graduate School of Medicine, Mayo Clinic College of Medicine - Fellow, Infectious Diseases 1973 - 1974

Mayo Graduate School of Medicine, Mayo Clinic College of Medicine - Fellow, Microbiology 1974 - 1975

Certification

Board Certifications

American Board of Internal Medicine (ABIM)

Internal Medicine 1973 - Present
Infectious Disease 1974 - Present

American Board of Pathology

Clinical Pathology 1975 - Present

Federation Licensing Examination (FLEX)

FLEX Exam 1992 - Present

Mayo Clinic Quality Academy

Mayo Clinic Quality Fellow: Bronze Level Certification 2012

Licensure

Texas	04363 (Medical)	01/1967 - Present
Minnesota	019639 6 (Medical)	01/1971 - Present
Arizona	18906 (Medical)	01/1989 - Present
Hawaii	8559 (Medical)	01/1993 - Present
Iowa	30976 (Medical)	01/1995 - Present

Honors and Awards

Alpha Omega Alpha - Alpha Omega Alpha Honor Medical Society	01/1966
Scholastic Honor - Baylor College of Medicine	01/1967
Teacher of the Year - Department of Internal Medicine, Mayo Graduate School of Medicine, Mayo Clinic College of Medicine	01/1977
Teacher of the Year - Department of Internal Medicine, Mayo Graduate School of Medicine, Mayo Clinic College of Medicine	01/1980
Teacher of the Year - Department of Internal Medicine, Mayo Graduate School of Medicine, Mayo Clinic College of Medicine	01/1983
Teacher of the Year/Hall of Fame - Mayo Graduate School of Medicine, Mayo Clinic College of Medicine	01/1986
Distinguished Faculty Service Award - Mayo Medical School, Mayo Clinic College of Medicine	01/1988
Teacher of the Year Hall of Fame - Department of Internal Medicine, Mayo Graduate School of Medicine, Mayo Clinic College of Medicine	01/1993
Marion D. Hargrove, Jr., Lectureship - Department of Medicine, Louisiana State University	01/1994
T. Duckett Jones Lecture - American Heart Association	01/1995
11th Annual L. L. Braun Lecture - Illinois Masonic Medical Center, Rush Medical College	01/1996
Excellence in Leadership Award - Mayo Clinic	01/1997
Distinguished Lecturer - Department of Internal Medicine, Medical Sciences	01/1998
Mayo Distinguished Clinician Award - Mayo Foundation	01/2000
Teacher of the Year Award, Mayo Fellows Association - Subspecialties - Department of Internal Medicine, Mayo Graduate School of Medicine, Mayo Clinic College of Medicine	01/2005
Henry S. Plummer Distinguished Physician Award - Office of Faculty Development, Department of Medicine, Mayo Clinic	2006
Mayo Pharmaceutical Formulary Committee - Excellence Through Teamwork Award, Rochester, Minnesota	2006
Edward G. Rosenow, III, M.D. Professorship in the Art of Medicine - Board of Trustees, Mayo Clinic, Rochester, Minnesota	2008
Teacher of the Year Hall of Fame, Mayo Fellows Association for the Department of Medicine - Subspecialties - Department of Internal Medicine, Mayo Graduate School of Medicine, Mayo Clinic College of Medicine	04/2008
2010-2011 Top Educator (top 20%) - Department of Medicine, Internal Medicine Residency Program, Mayo Clinic, Rochester, Minnesota	07/2010 - 06/2011

Outstanding Teaching Award for Education Mentor - Internal Medicine Residency, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota	2011
Rochester Distinguished Mayo Educator - Infectious Diseases - Mayo Clinic Education Committee, Mayo Clinic Committees, Rochester, Minnesota	2012
Teacher of the Year Award - Subspecialties - Teacher of the Year by the Mayo Fellows' Association, Rochester, Minnesota	2012
Top Educator in Resident Education (top 20%) - Department of Medicine, Internal Medicine Residency Program, Rochester, Minnesota	2012 - 2013
2012-2013 Top Educator for Resident Education (Top 20%) - Internal Medicine Residency Program, Department of Internal Medicine, Mayo Clinic	07/2012 - 06/2013
Excellence in Teaching - Department of Medicine, Internal Medicine Residency Program, Rochester, Minnesota	2013 - 2014
Plummer Society Award for Excellence - Mayo Clinic Alumni Association, Mayo Clinic College of Medicine, Rochester, Minnesota	2013
2013-2014 Top Educator - Department of Medicine, Internal Medicine Residency Program, Rochester, Minnesota	07/2013 - 06/2014
2014-2015 Top Educator (top 30%) - Department of Medicine, Internal Medicine Residency Program, Rochester, Minnesota	07/2014 - 06/2015
2015-2016 Top Educator - Department of Medicine, Internal Medicine Residency Program, Mayo Clinic, Rochester, Minnesota	07/2015 - 06/2016
Cierny Memorial Award - Musculoskeletal Infection Society, Cleveland, Ohio The award is given to institutions who exhibit excellence in orthopedics and treatment of infectious diseases	07/2015
2015 Clinical Teacher Award - Infectious Diseases Society of America	10/2015
Distinguished Alumnus Award - Baylor College of Medicine Alumni Association, Houston, Texas	04/2017

Military Service

- U.S.N.C.S. Morocco, United States Navy	01/1968 - 01/1970
--	-------------------

Previous Professional Positions and Major Appointments

Instructor in Medicine - Mayo Clinic College of Medicine and Science	07/1975 - 07/1977
Assistant Professor in Medicine - Mayo Clinic College of Medicine and Science	07/1977 - 07/1981
Consultant (Joint Appointment) - Division of Clinical Microbiology, Tissue Pathology and Tissue Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota	1980 - 1986
Director - Research Laboratory, Division of Infectious Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota	1981 - 1992
Associate Professor in Medicine - Mayo Clinic College of Medicine and Science	07/1981 - 07/1984
Assistant Professor in Microbiology - Mayo Clinic College of Medicine and Science	07/1984 - 05/2011

Teaching/Examining Privileges in Internal Medicine - Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic College of Medicine and Science 01/1988 - 01/1995

Chair - Division of Infectious Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 1990 - 2000

Professional and Community Memberships, Societies, and Services

Professional Memberships and Services

Academy for International Medical Studies Member	01/1985 - 12/1987
Alpha Omega Alpha Honor Medical Society Member	
American Board of Internal Medicine Subspecialty Board in Infectious Diseases Member	01/1992 - 12/1998
American College of Chest Physicians Fellow	
Master	2003
Committee on Cardiopulmonary Infections Member	01/1979 - 12/1983
Steering Committee on Infectious Diseases Member	01/1979 - 12/1983
American Federation for Clinical Research Fellow	
American Heart Association Ad Hoc Committee on Infective Endocarditis Member	01/1980 - 12/1981
Member	01/1987 - Present
Council on Cardiovascular Disease in the Young Member	01/1988 - Present
American Society for Microbiology Member	
European Working Group Management of Infective Endocarditis, Statement of Management of Streptococcal Endocarditis Member	01/1992 - 01/1998
Policy Statement for Management of Infective Endocarditis Member	01/1992
Food and Drug Administration Subcommittee on Treatment of bacteremia and Infective Endocarditis Member	01/1989 - 12/1992
Chair	01/1989 - 12/1992
Infectious Diseases Society of America Fellow	

Clinical Affairs Committee	
Member	01/1985 - 12/1988
Publications Committee	
Member	01/1992 - 12/1996
International Committee on Treatment of Infective Endocarditis	
Member	01/1985 - Present
Co-Chair	01/1985 - Present
International Society of Infective Endocarditis	
Member	01/1994 - Present
Organizing Committee	
Member	01/1994 - Present
Council Member	01/1994 - Present
International Steering Committee	
Infective Endocarditis Subcommittee	
Chair	01/1983 - 01/1986
Member	01/1983 - 01/1986
Prevention of Infections of Vascular Grafts and Prostheses Subcommittee	
Member	01/1984 - Present
Executive Board Member	01/1984 - Present
Musculoskeletal Infection Society of America	
Fellow	
National Committee for Clinical Laboratory Standards	
Area Committee	
Division of Microbiology	
Advisor	01/1996 - 01/1997
Member	01/1996 - 01/1997
Infective Endocarditis Subcommittee	
Member	01/1978 - 01/1980
Subcommittee on Antimicrobial Susceptibility Testing	
Member	01/1989 - 01/1997
Reviewer	01/2002 - 12/2014
Subcommittee on Enterococci	
Member	01/1991 - 01/1996
National Foundation for Infectious Diseases	
Member	01/1985 - 12/1988
Midwestern Division	
Board of Governors	
Member	01/1985 - 01/1988
Sigma Xi, The Scientific Research Society	
Member	
Task Force Medical Industry Relations Committee	
Member	01/1989 - Present
Walker Art Center Planning Committee, Medicine of Art Lecture Series	

Member

01/1997 - 12/1998

Journal Responsibilities**Journal Editorial Responsibilities**

Infectious Diseases and Clinical Microbiology
 Editorial Board Member

Journal Other Responsibilities

Mayo Clinic Health Letter

Reviewer

01/1985 - 12/1998

Mayo Clinical Advisory Board

Reviewer

01/1985 - 12/1998

Educational Activities**Teaching Intramural**

Faculty Infectious Diseases Course I
 Mayo Medical School
 Rochester, Minnesota

01/1974 - Present

Faculty Infectious Diseases Course II
 Mayo Medical School
 Rochester, Minnesota

01/1974 - Present

Faculty Infectious Diseases Course III
 Mayo Medical School
 Rochester, Minnesota

01/1974 - Present

Faculty Infectious Diseases Course IV
 Mayo Medical School
 Rochester, Minnesota

01/1974 - Present

ID Core Curriculum-Controversies in Endocarditis, Research Implications
 MSGME
 Rochester, Minnesota

01/29/2016

Institutional/Departmental Administrative Responsibilities, Committee Memberships, and Other Activities**Mayo Clinic**

Mayo Clinic Committees

Compliance Committee

Chair

Grand Rounds Committee

Member

01/1977 - 12/1986

Health-Related Sciences Education Committee

Member	01/1985 - 12/1987
Pharmaceutical Formulary Committee - Mayo Clinic	
Chair	
Subspecialty Residency Review Committee	
Member	01/1982 - 12/1983
Mayo Clinic Task Forces/Work Groups	
Antibiotic Advisory Focus Group	
Member	01/1998 - Present
Chair	01/1998 - 12/1998
Task Force of Antimicrobial Usage	
Chair	01/1988 - Present
Member	01/1988 - Present
Mayo Foundation for Medical Education and Research	
Advanced Clinical Residency Program in Infectious Diseases	
Director	01/1975 - 12/1983
Member	01/1975 - 12/1983
Mayo Clinic in Rochester	
Department of Facilities & Support Services	
Engineering, Media and Systems Coordination	
Ad Hoc Committee	
Member	01/1976 - 12/1977
Department of Health Sciences Research	
Ad hoc Committee	
Member	01/1985 - 01/1987
Department of Internal Medicine	
Administrative Committee	
Member	01/1990 - 12/1999
Division of Infectious Diseases	
Research Committee	
Chair	01/1975 - 01/1983
Member	01/1975 - 01/1983
Research Laboratory	
Member	01/1981 - 01/1992
Director	01/1981 - 01/1992
Hospital Committee	

Chair	01/1998 - 01/2000
Member	01/1998 - 01/2000
Inpatient Practice	
Member	01/1999 - 01/2000
Associate Chair	01/1999 - 01/2000
Leadership Committee	
Member	01/1999 - 01/2000
Operations Committee	
Member	01/2000
Hospital Master Planning Group	
Member	01/1997 - 12/1999
Mayo Clinic Rochester Committees	
Clinical Practice Committee - Rochester	
Hospital Leadership Team	
Member	01/1998 - Present
Pharmacy and Therapeutics Subcommittee - Rochester	
Member	01/1977 - 12/1988
Member	01/1984 - 12/1988
Chair	01/1984 - 12/1988
Clinical Reviews Committee	
Member	01/1983 - 12/1987
Education Committee	
Member	
Executive Clinical Reviews Committee	
Member	01/1984 - 12/1986
Finance Committee - Rochester	
Member	
Mayo Clinic Rochester - Executive Board	
Member	01/2006 - Present
Nursing Practice Council	
Member	01/1998 - 12/2000
Officers & Councilors of Staff - Rochester	
Member	01/1985 - 12/1987
Councilor-at-Large	01/1985 - 12/1987
Personnel Committee - Rochester	

Member

Presentations Extramural**National or International****Invited**

Session: Management of Endocarditis: An Update--Is this the end of endocarditis prophylaxis as we have known it? 09/07/2014

ICAAC 2014

Washington, District of Columbia

Vascular Graft Infections 05/09/2015

Mayo Clinic Infectious Diseases Subspecialties Update

Amelia Island, Florida

Session Chair: Robert Moellering Memorial Lecture 05/14/2015

10th International Symposium on Antimicrobial Agents and Resistance (ISAAR)

Incheon, South Korea

Diagnosis and Management of Vascular Graft Infection 05/15/2015

10th International Symposium on Antimicrobial Agents and Resistance (ISAAR)

Incheon, South Korea

Management for healthcare-associated bacterial infections: Prosthetic valve endocarditis 05/15/2015

10th International Symposium on Antimicrobial Agents and Resistance (ISAAR)

Incheon, South Korea

Should we ignore endocarditis prophylaxis guidelines? 09/18/2015

Challenges in Clinical Cardiology

Chicago, Illinois

Antibiotic stewardship: The way forward or back to the future? 09/14/2017 - 09/16/2017

Keynote Lecture - Are we facing post-antibiotic era?

11th International Symposium on Antimicrobial Agents and Resistance (ISAAR) and 3rd International Interscience Conference on Infection and Chemotherapy (ICIC)

Busan, South Korea

Community-associated MRSA infections 09/14/2017 - 09/16/2017

Chair, Symposium 1

11th International Symposium on Antimicrobial Agents and Resistance (ISAAR) and 3rd International Interscience Conference on Infection and Chemotherapy (ICIC) Start Date

Busan, South Korea

Poster

Five-year mortality of infective endocarditis in a population-based cohort	04/02/2016 - 04/04/2016
American College of Cardiology (ACC) Chicago, Illinois	
Impact of the American Heart Association's 2007 Guidelines on the practice of dental prophylaxis in patients at high risk for endocarditis in Olmsted County, Minnesota	04/02/2016 - 04/04/2016
American College of Cardiology (ACC) Chicago, Illinois	

Regional**Invited**

Career Choices in Infectious Diseases: Tips on How to be More Competitive 10th Annual Midwest Infectious Diseases Fellows Forum Rochester, Minnesota	05/03/2013
The Great Plague of the 14th Century: From Baghdad to the White House Learning is ForEver (LIFE) Rochester, Minnesota	10/14/2013

Visiting Professorship**Visiting Professorships**

1st Annual Raymond D. Pruitt, M.D. Lecture, Baylor Grand Rounds - "SBE Prophylaxis: From Osler to the Myth of Sisyphus?" Baylor College of Medicine Houston, Texas	01/08/2015
--	------------

Research Interests

Infective endocarditis
Endovascular infections
Device infections
Animal models of infection
New antimicrobial agents - in vitro, experimental infections and clinical trials
Musculoskeletal infections
Blood cultures

Research Grants Awarded**Completed Grants****Foundation**

Co-Investigator	RU 004 Treatment Of Penicillin Resistant Pneumonococcal Experimental Pneumonia. Funded by Roussel UCLAF. (Roussel #8)	03/1995 - 09/1995
-----------------	---	-------------------

Co-Investigator	RU 59863 Treatment Of Methicillin-Susceptible Staphylococcus Aureus Experimental Endocarditis. Funded by Roussel UCLAF. (Roussel #6)	03/1995 - 11/1995
Co-Investigator	RU 004 Treatment Of Haemophilus Influenzae Type B Experimental Pneumonia. Funded by Roussel UCLAF. (Roussel #7)	03/1995 - 02/1996
Co-Investigator	RU 59863 Treatment Of Experimental Pseudomonas Aeruginosa Pneumonia. Funded by Roussel UCLAF. (Roussel #9)	03/1995 - 02/1996
Co-Investigator	HMR 3647 Treatment of Haemophilus Influenzae Experimental Pneumonia. Funded by Roussel UCLAF. (Steckelberg 1)	08/1997 - 10/2000
Co-Investigator	Dental and Other Invasive Procedures and the Risk of Prosthetic Joint Infection: A Hospital Based Case-Control Study. Funded by Orthopaedic Research and Education Foundation. (OREF #15)	07/2004 - 06/2006
Co-Investigator	Development of a Clinical Prediction Rule for Use of Transesophageal Echocardiography for Managing S. aureus Bacteremia. Funded by American Heart Association - Midwest Affiliate. (12CRP12080058)	07/2012 - 06/2015

Industry

Co-Investigator	Clarithromycin Prophylaxis Of Viridan Streptococci Endocarditis. Funded by Abbott Laboratories. (Abbott #34)	04/1993 - 04/1994
Co-Investigator	The Effect Of CT-1501R On Antimicrobial Treatment Of Experimental Pneumonia. Funded by Cell Therapeutics, Inc.. (Cell #1)	05/1993 - 05/1994
Co-Investigator	Bay y 3118 Treatment Of Experimental HAemophilus Influenzae Pneumonia. Funded by Miles/Bayer Pharmaceuticals. (Miles #38)	07/1993 - 04/1994
Co-Investigator	Bay y 3118 Treatment Of Experimental Streptococcus Pneumoniae Pneumonia. Funded by Miles/Bayer Pharmaceuticals. (Miles #37)	07/1993 - 06/1994
Co-Investigator	Combination Treatment Of Multidrug Resistant Enterococcal Experimental Endocarditis With Cell-Wall Active Agents. Funded by Merck Research Laboratories. (Merck #88)	09/1993 - 08/1994
Co-Investigator	Azithromycin Prophylaxis Of Viridans Streptococci Endocarditis. Funded by Pfizer Inc.. (Pfizer #36)	01/1994 - 12/1994
Co-Investigator	Cefotaxime Plus Ofloxacin Treatment Of Methicillin-Susceptible Staphylococcus Aureus Experimental Endocarditis. Funded by Hoechst-Roussel Pharmaceutical Inc.. (Hoechst #18)	03/1994 - 02/1995
Co-Investigator	Ceftriaxone Prophylaxis Of Viridans Streptococcal Endocarditis. Funded by Hoffmann-La Roche Incorporated. (Roche #34)	06/1994 - 05/1995
Co-Investigator	L-Ofloxacin Plus Cefotaxime Treatment Of Methicillin-Sensitive Staphylococcus Aureus Experimental Osteomyelitis. Funded by R. W. Johnson Pharmaceutical Research Institute. (Johnson #11)	10/1994 - 10/2000
Co-Investigator	Ceftriaxone Treatment Of Penicillin Susceptible Pneumococcal Experimental Pneumonia. Funded by Hoffmann-La Roche Incorporated. (Roche #35)	12/1994 - 10/2000
Co-Investigator	CP 99,219 Treatment Of Penicillin-Resistant Pneumococcal Experimental Pneumonia 0CP 99,219 Treatment Of Penicillin-Resistant Pneumococcal Experimental Pneumonia. Funded by Pfizer Inc.. (Pfizer #39)	01/1995 - 06/1995

Co-Investigator	Synercid Treatment Of Methicillin-Susceptible Staphylococcus Aureu Experimental Osteomyelitis. Funded by Rhone-Poulenc Rorer	03/1995 - 02/1996
Co-Investigator	CP 99,219 Treatment Of Penicillin Resistant Pneumococcal Experimental Pneumonia. Funded by Pfizer Inc.. (Pfizer #39)	07/1995 - 06/1996
Co-Investigator	In Vivo Activity of Venoglobulin I Against Invasive Group A Streptococci. Funded by Alpha Therapeutic Corporattion. (Alpha 8)	09/1995 - 06/1996
Co-Investigator	Azithromycin Treatment of Clarithromycin Susceptible or Clarithromycin Intermediately - Susceptible Haemophilus Influenzae Type B Experimental Pneumonia. Funded by Pfizer Inc.. (Pfizer #42)	11/1995 - 07/1996
Co-Investigator	Treatment of Penicillin-Resistant, Macrolide-Resistant Pneumococcal Experimental Pneumonia, ABT-773. Funded by Abbott Laboratories. (ABBOTT #80)	06/2000 - 05/2003

Mayo Clinic

Co-Investigator	Tuberculosis Transmission in a High Prevalence Country: Analysis by Conventional Epidemiological Methods and DNA Fingerprinting. Funded by Mayo CR20 Funding	01/2002 - 12/2004
-----------------	--	-------------------

Other

Cardiovascular Disease in the Young - Rheumatic Fever, Endocarditis, & Kawasaki Disease Committee American Heart Association San Diego, California	03/2015
International Statement on Prevention of Infective Endocarditis	03/2015 - 03/2015
PAN European Council	06/2015 - 07/2015
Cardiovascular Disease in the Young - Rheumatic Fever, Endocarditis, & Kawasaki Disease Committee American Heart Association Orlando, Florida	11/2015

Bibliography

Peer-reviewed Articles

1. Pruitt RD, Conway J, Grollman A, Horwitz D, Kirkendall WM, Goldberg LI, **Wilson WR**. Medical management of hypertension. *Postgrad Med*. 1963 Jul; 34:16-19. PMID:13972360
2. **Wilson WR**, Martin WJ, Wilkowske CJ, Washington JA 2nd. Anaerobic bacteremia. *Mayo Clin Proc*. 1972 Sep; 47(9):639-46. PMID:5073944
3. **Wilson WR**, Dolan CT, Washington JA 2nd, Brown AL Jr, Ritts RE Jr. Clinical significance of postmortem cultures. *Archives of Pathology & Laboratory Medicine*. 1972 Sep; 94(3):244-9. PMID:4559403
4. **Wilson WR**, Ritts RE Jr, Hermans PE. Abnormal chemotaxis in patients with cutaneous anergy (PCA). *J Reticuloendothel Soc*. 1975; 18:22A.
5. **Wilson WR**, Jaumin PM, Danielson GK, Giuliani ER, Washington JA II, Geraci JE. Prosthetic valve endocarditis. *Ann Intern Med*. 1975 Jun; 82(6):751-6. PMID:1138584
6. **Wilson WR**, Rosenblatt JE, Washington JA 2nd. Anaerobic bacteremia. *Conn Med*. 1975 Oct; 39(10):597-600. PMID:1212857
7. Molenaar DM, Palumbo PJ, **Wilson WR**, Ritts RE Jr. Leukocyte chemotaxis in diabetic patients and their first-degree relatives. *Diabetes*. 1976; 25:880-883. PMID:971792
8. **Wilson WR**, Hermans PE, Ritts RE Jr. Idiopathic late-onset immunoglobulin deficiency with functional T-cell deficiency. *Arch Intern Med*. 1976 Mar; 136:343-346. PMID:1083220
9. **Wilson WR**, Van Scoy RE, Washington JA 2nd. Incidence of bacteremia in adults without infection. *J Clin Microbiol*. 1976 Aug; 2(2):94-5. PMID:972185 PMCID:274139
10. **Wilson WR**, Ritts RE Jr, Hermans PE. Abnormal chemotaxis in patients with cutaneous anergy. *Mayo Clin Proc*. 1977 Mar; 52(3):196-201. PMID:300135
11. Geraci JE, Wilkowske CJ, **Wilson WR**, Washington JA 2nd. Haemophilus endocarditis. Report of 14 patients. *Mayo Clin Proc*. 1977 Apr; 52(4):209-15. PMID:846219
12. **Wilson WR**. Tetracyclines, chloramphenicol, erythromycin, and clindamycin. *Mayo Clin Proc*. 1977 Oct; 52(10):635-40. PMID:909315
13. Van Scoy RE, **Wilson WR**. Antimicrobial agents in patients with renal insufficiency. *Mayo Clin Proc*. 1977 Nov; 52(11):704-6. PMID:926846
14. Geraci JE, Greipp PR, Wilkowske CJ, **Wilson WR**, Washington JA 2nd. *Cardiobacterium hominis* endocarditis. Four cases with clinical and laboratory observations. *Mayo Clin Proc*. 1978 Jan; 53(1):49-53. PMID:625144
15. **Wilson WR**, Geraci JE, Danielson GK, Thompson RL, Spittell JA Jr, Washington JR 2nd, Giuliani ER. Anticoagulant therapy and central nervous system complications in patients with prosthetic valve endocarditis. *Circulation*. 1978 May; 57(5):1004-7. PMID:639199

16. **Wilson WR**, Geraci JE, Wilkowske CJ, Washington JA 2nd. Short-term intramuscular therapy with procaine penicillin plus streptomycin for infective endocarditis due to viridans streptococci. *Circulation*. 1978 Jun; 57(6):1158-61. PMID:639238
17. **Wilson WR**, Danielson GK, Giuliani ER, Washington JA II, Jaumin PM, Geraci JE. Valve replacement in patients with active infective endocarditis. *Circulation*. 1978 Oct; 58:585-588. PMID:688566
18. **Wilson WR**, Danielson GK, Giuliani ER, Washington JA 2nd, Jaumin PM, Geraci JE. Cardiac valve replacement in congestive heart failure due to infective endocarditis. *Mayo Clin Proc*. 1979 Apr; 54(4):223-6. PMID:423601
19. Bourgault AM, **Wilson WR**, Washington JA 2nd. Antimicrobial susceptibilities of species of viridans streptococci. *J Infect Dis*. 1979 Sep; 140(3):316-21. PMID:501146
20. Karchmer AW, Archer GL, Dismukes WE, Sande MA, Johnson DW Jr, **Wilson WR**. Staphylococcus epidermidis prosthetic valve endocarditis. pp. 904-906 in: *Proceedings of the 11th International Congress of Chemotherapy*. Am Society for Microbiology, 1980.
21. Geraci JE, **Wilson WR**, Washington JA 2nd. Infective endocarditis caused by *Actinobacillus actinomycetemcomitans*: report of four cases. *Mayo Clin Proc*. 1980 Jul; 55(7):415-9. PMID:7382550
22. Geraci JE, **Wilson WR**, Thompson JH Jr. Visceral leishmaniasis (kala-azar) as a cause of fever of unknown origin. *Mayo Clin Proc*. 1980 Jul; 55(7):455-8. PMID:6247584
23. **Wilson WR**, Nichols DR, Thompson RL, Giuliani ER, Geraci JE. Infective endocarditis: therapeutic considerations. *Am Heart J*. 1980 Nov; 100(5):689-704. PMID:7004153
24. McKenna UG, Meadows JA 3rd, Brewer NS, **Wilson WR**, Perrault J. Toxic shock syndrome, a newly recognized disease entity. Report of 11 cases. *Mayo Clin Proc*. 1980 Nov; 55(11):663-72. PMID:7442320
25. Matsumoto JY, **Wilson WR**, Wright AJ, Geraci JE, Washington JA II. Synergy of penicillin and decreasing concentrations of aminoglycosides against enterococci from patients with infective endocarditis. *Antimicrob Agents Chemother*. 1980 Dec; 18:944-947. PMID:7235680 PMID:352994
26. **Wilson WR**. Clinical brief: a new broad-spectrum cephalosporin. *Mayo Clin Proc*. 1981 Jan; 56:63.
27. Bisno AL, Dismukes WE, Durack DT, Kaplan EL, Karchmer AW, Kaye D, Sande MA, Sanford JP, **Wilson WR**. Treatment of infective endocarditis due to viridans streptococci. *Circulation*. 1981; 63:730-3. PMID:7460258
28. **Wilson WR**, Thompson RL, Wilkowske CJ, Washington JA 2nd, Giuliani ER, Geraci JE. Short-term therapy for streptococcal infective endocarditis. Combined intramuscular administration of penicillin and streptomycin. *JAMA*. 1981 Jan 23-30; 245(4):360-3. PMID:7452862
29. Geraci JE, **Wilson WR**. Vancomycin therapy for infective endocarditis. *Rev Infect Dis*. 1981 Nov-Dec; (3 Suppl):S250-8.
30. Golla JA, Larson LA, Anderson CF, Lucas AR, **Wilson WR**, Tomasi TB Jr. An immunological assessment of patients with anorexia nervosa. *Am J Clin Nutr*. 1981 Dec; 34(12):2756-62. PMID:6797290
31. Wright AJ, **Wilson WR**. Experimental animal endocarditis. *Mayo Clin Proc*. 1982 Jan; 57(1):10-4. PMID:7054619

32. Auckenthaler R, **Wilson W**, Wright A, Washington J, Durack D, Geraci J. Lack of in vivo and in vitro bactericidal activity of n-formimidoyl thenamycin against enterococci. *Antimicrobial Agents and Chemotherapy*. 1982; 22:448-52.
33. **Wilson WR**. Management of patients with infective endocarditis: a holistic approach. *J Gerogia Baptist Medical Center*. 1982; 1:24-7.
34. **Wilson WR**, Giuliani ER, Danielson GK, Geraci JE. General considerations in the diagnosis and treatment of infective endocarditis. *Mayo Clin Proc*. 1982 Feb; 57(2):81-5. PMID:7054626
35. **Wilson WR**, Giuliani ER, Geraci JE. Treatment of penicillin-sensitive streptococcal infective endocarditis. *Mayo Clin Proc*. 1982 Feb; 57(2):95-100. PMID:7054628
36. Geraci JE, **Wilson WR**. Endocarditis due to gram-negative bacteria: report of 56 cases. *Mayo Clin Proc*. 1982 Mar; 57:145-148. PMID:7062778
37. **Wilson WR**, Giuliani ER, Danielson GK, Geraci JE. Management of complications of infective endocarditis. *Mayo Clin Proc*. 1982 Mar; 57(3):162-70. PMID:6895923
38. **Wilson WR**, Danielson GK, Giuliani ER, Geraci JE. Prosthetic valve endocarditis. *Mayo Clin Proc*. 1982 Mar; 57(3):155-61. PMID:7062779
39. Thomson RB Jr, Smith TF, **Wilson WR**. Comparison of two methods used to prepare smears of mouse lung tissue for detection of *Pneumocystis carinii*. *J Clin Microbiol*. 1982 Aug; 16(2):303-6. PMID:6181088 PMID:272350
40. Wright AJ, Thompson RL, McLimans CA, **Wilson WR**, Washington JA 2nd. The antimicrobial removal device. A microbiological and clinical evaluation. *Am J Clin Pathol*. 1982 Aug; 78(2):173-7. PMID:7048940
41. Wright AJ, **Wilson WR**, Matsumoto JY, Washington JA 2nd, Geraci JE. Influence of gentamicin dose size on the efficacies of combinations of gentamicin and penicillin in experimental streptomycin-resistant enterococcal endocarditis. *Antimicrobial Agents & Chemotherapy*. 1982 Dec; 22(6):972-5. PMID:6818902 PMID:185703
42. **Wilson WR**, Geraci JE. Antibiotic treatment of infective endocarditis. *Annu Rev Med*. 1983; 34:413-27. PMID:6344769
43. **Wilson WR**. Antimicrobial chemoprophylaxis. *Med Clin North Am*. 1983 Jan; 67(1):99-112. PMID:6402624
44. **Wilson WR**, Geraci JE. Cardiac valve replacement in patients with active infective endocarditis. *HERZ*. 1983; 8:332-43. PMID:6662478
45. Estaben A, **Wilson WR**, Ruiz-Santana S, Fernandez-Segoviano F, Martinez-Cabruja R. Endocarditis caused by *B. fragilis*. *Chest*. 1983; 84:104-7. PMID:6861536
46. Brandenburg RO, Giuliani ER, **Wilson WR**, Geraci JE. Infective endocarditis--a 25 year overview of diagnosis and therapy. *J Am Coll Cardiol*. 1983 Jan; 1(1):280-91. PMID:6826938
47. **Wilson WR**, Cockerill FR 3rd. Tetracyclines, chloramphenicol, erythromycin, and clindamycin. *Mayo Clin Proc*. 1983 Feb; 58(2):92-8. PMID:6823163
48. Van Scoy RE, **Wilson WR**. Antimicrobial agents in patients with renal insufficiency. *Mayo Clin Proc*. 1983 Apr; 58(4):246-8. PMID:6834891

49. Henry NK, McLimans CA, Wright AJ, Thompson RL, **Wilson WR**, Washington JA 2nd. Microbiological and clinical evaluation of the isolator lysis-centrifugation blood culture tube. *J Clin Microbiol.* 1983 May; 17(5):864-9. PMID:6863507 PMID:272757
50. Cockerill FR 3rd, **Wilson WR**, Van Scoy RE. Traveling toothpicks. *Mayo Clin Proc.* 1983 Sep; 58(9):613-6. PMID:6350738
51. Pien FD, **Wilson WR**, Kunz K, Washington JA 2nd. *Aerococcus viridans* endocarditis. *Mayo Clin Proc.* 1984 Jan; 59(1):47-8. PMID:6694434
52. Mills J, Pulliam L, Dall L, Marzouk J, **Wilson WR**, Costerton J. Exopolysaccharide production by viridans streptococci in experimental endocarditis. *Infect Immun.* 1984; 43:359-67. PMID:6690410 PMID:263435
53. **Wilson WR**, Henry NK, Keys TF, Anhalt JP, Cockerill FR 3rd, Edson RS, Geraci JE, Hermans PE, Muller SM, Rosenblatt JE. Empiric therapy with moxalactam alone in patients with bacteremia. *Mayo Clin Proc.* 1984 May; 59(5):318-26. PMID:6727424
54. **Wilson WR**, Wilkowske CJ, Wright AJ, Sande MA, Geraci JE. Treatment of streptomycin-susceptible and streptomycin-resistant enterococcal endocarditis. *Ann Intern Med.* 1984 Jun; 100(6):816-23. PMID:6426359
55. Libertin CR, Woloschak GE, **Wilson WR**, Smith TF. Analysis of *Pneumocystis carinii* cysts with a fluorescence-activated cell sorter. *J Clin Microbiol.* 1984 Nov; 20: (5)877-80. PMID:6392322 PMID:271464
56. Morgan MA, **Wilson WR**, Neel HB 3rd, Roberts GD. Fungal sinusitis in healthy and immunocompromised individuals. *Am J Clin Pathol.* 1984 Nov; 82(5):597-601. PMID:6496403
57. Indrelie JA, **Wilson WR**, Matsumoto JY, Geraci JE, Washington JA 2nd. Synergy of imipenem or penicillin G and aminoglycosides against enterococci isolated from patients with infective endocarditis. *Antimicrobial Agents & Chemotherapy.* 1984 Dec; 26(6):909-12. PMID:6596907 PMID:180048
58. Libertin CR, **Wilson WR**, Roberts GD. *Candida lusitanae*--an opportunistic pathogen. *Diagn Microbiol Infect Dis.* 1985 Jan; 3: (1)69-71. PMID:3967474
59. Pulliam L, Dall L, Inokuchi S, **Wilson WR**, Hadley WK, Mills J. Effects of exopolysaccharide production by viridans streptococci on penicillin therapy of experimental endocarditis. *J Infect Dis.* 1985; 151:153-6. PMID:3965587
60. **Wilson WR**, Zak O, Sande MA. Penicillin therapy for treatment of experimental endocarditis caused by viridans streptococci in animals. *J Infect Dis.* 1985; 141:1028-33.
61. Rosenow EC III, Cockerill FR III, **Wilson WR**. Pulmonary complications in the immunocompromised host. *Curr Pulmonol.* 1985; 6:181-231.
62. Gleaves CA, Smith TF, Wold AD, **Wilson WR**. Detection of viral and chlamydial antigens in open-lung biopsy specimens. *Am J Clin Pathol.* 1985 Mar; 83(3):371-4. PMID:2983526
63. Washington JA 2nd, **Wilson WR**. Erythromycin: a microbial and clinical perspective after 30 years of clinical use (1). *Mayo Clin Proc.* 1985 Mar; 60(3):189-203. PMID:3974301
64. Washington JA 2nd, **Wilson WR**. Erythromycin: a microbial and clinical perspective after 30 years of clinical use (2). *Mayo Clin Proc.* 1985 Apr; 60(4):271-8. PMID:3884913
65. Backes RJ, **Wilson WR**, Geraci JE. Group B streptococcal infective endocarditis. *Arch Intern Med.* 1985 Apr; 145(4):693-6. PMID:3885892

66. **Wilson WR**, Geraci JE. Treatment of streptococcal infective endocarditis. *Am J Med.* 1985 Jun 28; 78(6B):128-37. PMID:3925771
67. Rosenow EC III, **Wilson WR**, Cockerill FRI. Pulmonary disease in the immunocompromised host. (First of two parts). *Mayo Clin Proc.* 1985 Jul; 60:473-487. PMID:2409412
68. Travis LB, Roberts GD, **Wilson WR**. Clinical significance of *Pseudallescheria boydii*: a review of 10 years' experience. *Mayo Clin Proc.* 1985 Aug; 60(8):531-7. PMID:3894816
69. Cockerill FR III, **Wilson WR**, Carpenter HA, Smith TF, Rosenow ECI. Open lung biopsy in immunocompromised patients. *Arch Intern Med.* 1985 Aug; 145(8):1398-404. PMID:2411238
70. **Wilson WR**, Cockerill FR 3rd, Rosenow EC 3rd. Pulmonary disease in the immunocompromised host (2). *Mayo Clin Proc.* 1985 Sep; 60(9):610-31. PMID:3894817
71. Griffin MR, **Wilson WR**, Edwards WD, O'Fallon WM, Kurland LT. Infective endocarditis. Olmsted County, Minnesota, 1950 through 1981. *JAMA.* 1985 Sep 6; 254(9):1199-202. PMID:4021062
72. Freidig EE, **Wilson WR**, Washington JA II, McClure SP, Banks PM. Clinical-Histologic-Microbiologic analysis of 419 lymph node biopsy specimens. *Rev Infect Dis.* 1986; 8:322-8. PMID:3726392
73. Southorn PA, Plevak DJ, Wright AJ, **Wilson WR**. Adverse effects of vancomycin administered in the perioperative period. *Mayo Clin Proc.* 1986 Sep; 61(9):721-4. PMID:3747614
74. Henry NK, **Wilson WR**, Roberts RB, Acar JF, Geraci JE. Antimicrobial therapy of experimental endocarditis caused by nutritionally variant viridans group streptococci. *Antimicrobial Agents & Chemotherapy.* 1986 Sep; 30(3):465-7. PMID:3777910 PMCID:180581
75. Backes RJ, Rouse MS, Henry NK, Geraci JE, **Wilson WR**. Activity of penicillin combined with an aminoglycoside against group B streptococci in vitro and in experimental endocarditis. *J Antimicrob Chemother.* 1986 Oct; 18(4):491-8. PMID:3771432
76. Henry NK, Schultz HJ, Grubbs NC, Muller SM, Ilstrup DM, **Wilson WR**. Comparison of ciprofloxacin and cotrimoxazole in the treatment of uncomplicated urinary tract infection in women. *J Antimicrob Chemother.* 1986 Nov; 18 Suppl D:103-6. PMID:3492486
77. Henry NK, **Wilson WR**, Geraci JE. Treatment of streptomycin-susceptible enterococcal experimental endocarditis with combinations of penicillin and low- or high-dose streptomycin. *Antimicrobial Agents & Chemotherapy.* 1986 Nov; 30(5):725-8. PMID:3800348 PMCID:176521
78. **Wilson WR**, Gersh BJ. Infective endocarditis: experimental and clinical developments. *Curr Opinion Cardiol.* 1987; 2:506-13.
79. Stratton CA, Aldridge KE, Barry AL, Reller LB, Sanders CC, Standiford HC, **Wilson WR**. Methods for determining bactericidal activity of antimicrobial agents. *The National Committee for Clinical Laboratory Standards and 7(2)35-74.* 1987; 7: (1)1-34.
80. Fernandez-Guerrero M, Rouse MS, Henry NK, Geraci JE, **Wilson WR**. In vitro and in vivo activity of ciprofloxacin against enterococci isolated from patients with infective endocarditis. *Antimicrobial Agents & Chemotherapy.* 1987 Mar; 31(3):430-3. PMID:3579260 PMCID:174745
81. Enzler MJ, **Wilson WR**, Giuliani ER. Noninvasive detection of cardiac abscesses complicating infective endocarditis. *American Journal of Noninvasive Cardiology.* 1987 Mar-Apr; 1:109-119.

82. Henry NK, Rouse MS, Whitesell AL, McConnell ME, **Wilson WR**. Treatment of methicillin-resistant *Staphylococcus aureus* experimental osteomyelitis with ciprofloxacin or vancomycin alone or in combination with rifampin. *Am J Med*. 1987 Apr 27; 82(4A):73-5. PMID:3578332
83. Enzler MJ, Rouse MS, Henry NK, Geraci JE, **Wilson WR**. In vitro and in vivo studies of streptomycin-resistant, penicillin-susceptible streptococci from patients with infective endocarditis. *J Infect Dis*. 1987 May; 155(5):954-8. PMID:3644854
84. McConnell ME, Sarria-Cepeda S, Rouse MS, Henry NK, **Wilson WR**. Comparative in vitro activity of the new penem CGP 31608. *Eur J Clin Microbiol*. 1987 Jun; 6(3):313-5. PMID:3622498
85. Musial CE, **Wilson WR**, Sinkeldam IR, Roberts GD. Recovery of *Blastomyces dermatitidis* from blood of a patient with disseminated blastomycosis. *J Clin Microbiol*. 1987 Aug; 25(8):1421-3. PMID:3624440 PMCID:269238
86. **Wilson WR**. Antimicrobial therapy of streptococcal endocarditis. *J Antimicrob Chemother*. 1987 Sep; 20 Suppl A:147-59. PMID:3316158
87. **Wilson WR**, Cockerill FR 3rd. Tetracyclines, chloramphenicol, erythromycin, and clindamycin. *Mayo Clin Proc*. 1987 Oct; 62 (10):906-15 PMID:3657308
88. Van Scoy RE, **Wilson WR**. Antimicrobial agents in adult patients with renal insufficiency: initial dosage and general recommendations. *Mayo Clin Proc*. 1987 Dec; 62 (12):1142-5 PMID:3682959
89. Fernandez-Guerrero M, Rouse MS, Henry NK, **Wilson WR**. Ciprofloxacin therapy of experimental endocarditis caused by methicillin-susceptible or methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother*. 1988; 32:747-51. PMID:3164989 PMCID:172264
90. **Wilson WR**, Gersh BJ. Infective endocarditis: experimental and clinical developments, antimicrobial therapy and management of complications. *Curr Opinion Cardiol*. 1988; 3:400-4.
91. Busk MF, Rosenow EC 3rd, **Wilson WR**. Invasive procedures in the diagnosis of pneumonia. *Semin Respir Infect*. 1988 Jun; 3(2):113-22. PMID:3041512
92. Disno AL, Dismukes WE, Durack DT, Kaplan EL, Karchmer AW, Kaye D, Rahimotoola SH, Sande MA, Sanford JP, Watanakunakorn C, **Wilson WR**. Antimicrobial treatment of infective endocarditis due to viridans streptococci, enterococci, and staphylococci *JAMA*. 1989; 261:1471-7. PMID:2645447
93. **Wilson WR**. Cardiac infections. *Curr Opinion Infect Dis*. 1989; 2:202-5.
94. Paya CV, **Wilson WR**. Gram-negative infective endocarditis. *Infect Dis Clin Microbiol*. 1989; 7:8-11.
95. **Wilson WR**, Gersh BJ. Infective endocarditis. *Curr Opinion Cardiol*. 1989; 4:423-7.
96. Steckelberg JM, Keating MR, Rouse MS, **Wilson WR**. Lack of extracellular slime effect on treatment outcome of *Staphylococcus epidermidis* experimental endocarditis. *J Antimicrob Chemother*. 1989 Jan; 23(1):117-21. PMID:2745247
97. Carty G, Meland NB, Jong G, **Wilson WR**. Ruptured dissecting hepatic artery aneurysm: a rare cause of abdominal apoplexy. *Vasc Surg*. 1989; 23:327-312.
98. Gerecht WB, Henry NK, Hoffman WW, Muller SM, LaRusso NF, Rosenblatt JE, **Wilson WR**. Prospective randomized comparison of mezlocillin therapy alone with combined ampicillin and gentamicin therapy for patients with cholangitis. *Arch Intern Med*. 1989 Jun; 149(6):1279-84. PMID:2658897

99. Rouse MS, Wilcox RM, Henry NK, Steckelberg JM, **Wilson WR**. Ciprofloxacin therapy of experimental endocarditis caused by methicillin-resistant *Staphylococcus epidermidis*. *Antimicrob Agents Chemother*. 1990 Feb; 34(2):273-6. PMID:2327776 PMID:171572
100. Steckelberg JM, Melton LJ 3rd, Ilstrup DM, Rouse MS, **Wilson WR**. Influence of referral bias on the apparent clinical spectrum of infective endocarditis. *Am J Med*. 1990 Jun; 88 (6):582-8 PMID:2346159
101. Ormand JE, Talley NJ, Carpenter HA, Shorter RG, Conley CR, **Wilson WR**, DiMugno EP, Zinsmeister AR, Phillips SF. [¹⁴C]urea breath test for diagnosis of *Helicobacter pylori*. *Dig Dis Sci*. 1990 Jul; 35 (7):879-84 PMID:2364842
102. **Wilson WR**, Khan A, Laws ER Jr. Transseptal approaches for pituitary surgery. *Laryngoscope*. 1990 Aug; 100 (8):817-9. PMID:2381256
103. Guess HA, Resseguie LJ, Melton LJ 3rd, Kurland LT, Lydick EG, Aksamit AJ, **Wilson WR**. Factors predictive of seizures among intensive care unit patients with gram-negative infections. *Epilepsia*. 1990 Sep-Oct; 31 (5):567-73. PMID:2401248
104. Bayer AS, Hutter AM, **Wilson WR**. Current management of infective endocarditis *Patient Care*. 1991; 25:15-37.
105. Ormand JE, Talley NJ, Shorter RG, Conley CR, Carpenter HA, Fich A, **Wilson WR**, Phillips SF. Prevalence of *Helicobacter pylori* in specific forms of gastritis. Further evidence supporting a pathogenic role for *H. pylori* in chronic nonspecific *Dig Dis Sci*. 1991 Feb; 36 (2):142-5 PMID:1988256
106. **Wilson WR**. Treatment of infections caused by anaerobes. *J Chemother*. 1991 Feb; 3 Suppl 2:7-11. PMID:2040901
107. Steckelberg JM, Murphy JG, Ballard D, Bailey K, Tajik AJ, Taliencio CP, Giuliani ER, **Wilson WR**. Emboli in infective endocarditis: the prognostic value of echocardiography. *Ann Intern Med*. 1991 Apr 15; 114: (8)635-40. PMID:2003709
108. Dorsher CW, Rosenblatt JE, **Wilson WR**, Ilstrup DM. Anaerobic bacteremia: decreasing rate over a 15-year period. *Rev Infect Dis*. 1991 Jul-Aug; 13(4):633-6. PMID:1925283
109. Steckelberg JM, Khandheria BK, Anhalt JP, Ballard DJ, Seward JB, Click RL, **Wilson WR**. Prospective evaluation of the risk of bacteremia associated with transesophageal echocardiography. *Circulation*. 1991 Jul; 84(1):177-80. PMID:2060093
110. Talley NJ, Newell DG, Ormand JE, Carpenter HA, **Wilson WR**, Zinsmeister AR, Perez-Perez GI, Blaser MJ. Serodiagnosis of *Helicobacter pylori*: comparison of enzyme-linked immunosorbent assays. *J Clin Microbiol*. 1991 Aug; 29: (8)1635-9. PMID:1761685 PMID:270176
111. Smilack JD, **Wilson WR**, Cockerill FR 3rd. Tetracyclines, chloramphenicol, erythromycin, clindamycin, and metronidazole. *Mayo Clin Proc*. 1991 Dec; 66 (12):1270-80 PMID:1749296
112. **Wilson WR**. Ceftriaxone therapy of penicillin-susceptible streptococcal endocarditis *JAMA*. 1992; 267:279-80. PMID:1727528
113. Rouse MS, Tallan BM, Steckelberg JM, Henry NK, **Wilson WR**. Efficacy of cilofungin therapy administered by continuous intravenous infusion for experimental disseminated candidiasis in rabbits. *Antimicrob Agents Chemother*. 1992 Jan; 36(1):56-8. PMID:1590700 PMID:189225

114. Bisno AL, Dismukes WE, Durack DT, Kaplan EL, Karchmer AU, Kaye D, Rahimtoola SH, Sande MA, Sanford JP, Watanakunakorn C, **Wilson WR**. Guidelines for the diagnosis of rheumatic fever. JAMA. 1992; 268:2069-73. PMID:1404745
115. **Wilson WR**, Mosiman F. Prophylaxis and treatment of infections complicating abdominal surgery J Hosp Infect. 1992; 22(suppl A):3-8. PMID:1362747
116. Henry NK, Steckelberg JM, **Wilson WR**. The Clinical Use of Penicillin - Revisited. Mayo Clin Proc. 1992; 67:1128.
117. **Wilson WR**. Recognition and treatment of infective endocarditis. Heart Disease & Stroke. 1992 Mar-Apr; 1 (2):64-7. PMID:1344089
118. Rouse MS, Tallan BM, Henry NK, Steckelberg JM, **Wilson WR**. Animal models as predictors of outcome of therapy with broad spectrum cephalosporins. J Antimicrob Chemother. 1992 Apr; 29(Suppl A):39-45. PMID:1601755
119. **Wilson WR**. Fluoroquinolone therapy. The Practice of Internal Medicine-1992. 1992 May 11-15; 243:
120. Hellinger WC, Rouse MS, Rabadan PM, Henry NK, Steckelberg JM, **Wilson WR**. Continuous intravenous versus intermittent ampicillin therapy of experimental endocarditis caused by aminoglycoside-resistant enterococci. Antimicrob Agents Chemother. 1992 Jun; 36(6):1272-5. PMID:1416826 PMCID:190330
121. **Wilson WR**, Gilbert DN, Bisno AL, Freedman LR, Smith C, Drusano G, Kaye D. Evaluation of new anti-infective drugs for the treatment of infective endocarditis. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis. 1992 Nov; 15 Suppl 1:S89-95. PMID:1477254
122. Grubbs NC, Schultz HJ, Henry NK, Ilstrup DM, Muller SM, **Wilson WR**. Ciprofloxacin versus trimethoprim-sulfamethoxazole: treatment of community-acquired urinary tract infections in a prospective, controlled, double-blind comparison. Mayo Clin Proc. 1992 Dec; 67 (12):1163-8 PMID:1469927
123. Henry NK, Steckelberg JM, **Wilson WR**. Historical profiles of Mayo. The clinical use of penicillin--revisited. Mayo Clin Proc. 1992 Dec; 67:1128.
124. Dajani AS, Taubert KA, Gerber MA, Shulman ST, Ferrieri P, Freed M, Takahashi M, Bierman FZ, Karchmer AW, **Wilson WR**, Rahimtoola SH, Durack DT, Peter G. Diagnosis and therapy of Kawasaki Disease in Children Circulation. 1993; 87:1776-80. PMID:8491037
125. Steckelberg JM, Rouse MS, Tallan BM, Osmon DR, Henry NK, **Wilson WR**. Relative efficacies of broad-spectrum cephalosporins for treatment of methicillin-susceptible Staphylococcus aureus experimental infective endocarditis. Antimicrob Agents Chemother. 1993 Mar; 37(3):554-8. PMID:8460924 PMCID:187706
126. Steckelberg JM, **Wilson WR**. Risk factors for infective endocarditis. Infect Dis Clin North Am. 1993 Mar; 7(1):9-19. PMID:8463656
127. Ang BS, Telenti A, King B, Steckelberg JM, **Wilson WR**. Candidemia from a urinary tract source: microbiological aspects and clinical significance. Clin Infect Dis. 1993 Oct; 17(4):662-6. PMID:8268347
128. Dajani AS, Taubert KA, Takahashi M, Bierman FZ, Freed M, Ferrieri P, Gerber M, Shulman ST, Karchmer AW, **Wilson WR**, Peter G, Durack DT, Rahimtoola S. Guidelines for long-term management of patients with Kawasaki Disease Circulation. 1994; 89:916-22. PMID:8313588
129. **Wilson WR**. Introduction. Curr Ther Res Clin Exp. 1994; 55(Suppl A):1.

130. **Wilson WR.** Management of complications of infective endocarditis Proceedings to 4th WPCCID Supplement to JAMA Southeast Asia December , pp 176-179. 1994; 0: 0.
131. **Wilson WR.** New advances in oral antibiotic therapy: efficacy, safety, and compliance. Proceedings to 4th WPCCID Supplement to JAMA Southeast Asia December , pp 34-305. 1994; 0: 0.
132. **Wilson WR.** Tolerance and safety of orally administered antimicrobial agents--an important factor in the selection of drug therapy. *Curr Ther Res Clin Exp.* 1994; 55(Suppl A):49-56.
133. Brandt CM, Rouse MS, Tallan BM, **Wilson WR**, Steckelberg JM. Failure of time-kill synergy studies using subinhibitory antimicrobial concentrations to predict in vivo antagonism of cephalosporin-rifampin combinations against *Staphylococcus aureus*. *Antimicrob Agents Chemother.* 1994 Sep; 38: (9)2191-3. PMID:7811044
PMCID:284709
134. **Wilson WR**, Karchmer AW, Bisno AL, Dajani AS, Taubert KA, Bayer A, Kaye D, Ferrieri P, Shulman ST, Durack DT. Antibiotic treatment of adults with infective endocarditis due to viridans streptococci, enterococci, other streptococci, staphylococci, and HACEK microorganisms. *JAMA.* 1995; 274:1706-13. PMID:7474277
135. Steele RW, **Wilson WR.** Challenges in the management of upper respiratory tract infection. *Infect Med.* 1995; 12(suppl):26-32.
136. Dajani A, Taubert K, Ferrieri P, Peter G, Shulman S, Bayer A, Bolger A, Gewitz M, Hutto C, Newburger J, Nouri S, **Wilson WR.** Treatment of acute streptococcal pharyngitis and prevention of rheumatic fever: a statement for health professionals *Pediatr.* 1995; 96:758-64.
137. **Wilson WR.** Selection of cephalosporins for hospital formularies. *Diagnostic Microbiology & Infectious Disease.* 1995 May-Jun; 22(1-2):129-34. PMID:7587026
138. Brandt CM, Rouse MS, Tallan BM, Laue NW, **Wilson WR**, Steckelberg JM. Effective treatment of cephalosporin-rifampin combinations against cryptic methicillin-resistant beta-lactamase-producing coagulase-negative staphylococcal experimental endocarditis. *Antimicrob Agents Chemother.* 1995 Aug; 39(8):1815-9. PMID:7486924 PMCID:162831
139. MacMorran WS, Badley AD, **Wilson WR.** 26-year-old man with HIV infection and abdominal pain. *Mayo Clin Proc.* 1995 Sep; 70(9):885-8. PMID:7643643 DOI:10.1016/S0025-6196(11)63947-5
140. Pechere JC, **Wilson W**, Neu H. Laboratory assessment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins. *J Antimicrob Chemother.* 1995 Nov; 36(5):757-71. PMID:8626256
141. Cockerill FR 3rd, Williams DE, Eisenach KD, Kline BC, Miller LK, Stockman L, Voyles J, Caron GM, Bundy SK, Roberts GD, **Wilson WR**, Whelen AC, Hunt JM Jr, Persing DH. Prospective evaluation of the utility of molecular techniques for diagnosing nosocomial transmission of multidrug-resistant tuberculosis. *Mayo Clin Proc.* 1996 Mar; 71(3):221-9. PMID:8594278 DOI:10.1016/S0025-6196(11)63959-1
142. Brandt CM, Rouse MS, Laue NW, Stratton CW, **Wilson WR**, Steckelberg JM. Effective treatment of multidrug-resistant enterococcal experimental endocarditis with combinations of cell wall-active agents. *J Infect Dis.* 1996 Apr; 173(4):909-13. PMID:8603970
143. Patel R, Osmon DR, Steckelberg JM, Dekutoski MB, **Wilson WR.** Vertebral osteomyelitis due to *Shigella boydii*. *Clin Infect Dis.* 1996 May; 22(5):863-4. PMID:8722953

144. Brandt CM, Warner CB, Rouse MS, Steckelberg JM, **Wilson WR**. Effect of gentamicin dosing interval on efficacy of penicillin or ceftriaxone treatment of experimental endocarditis due to penicillin-susceptible, ceftriaxone-tolerant viridans group streptococci. *Antimicrob Agents Chemother*. 1996 Dec; 40(12):2901-3. PMID:9124865 PMCID:163646
145. Cockerill FR 3rd, MacDonald KL, Thompson RL, Roberson F, Kohner PC, Besser-Wiek J, Manahan JM, Musser JM, Schlievert PM, Talbot J, Frankfort B, Steckelberg JM, **Wilson WR**, Osterholm MT. An outbreak of invasive group A streptococcal disease associated with high carriage rates of the invasive clone among school-aged children. *JAMA*. 1997 Jan 1; 277: (1)38-43. PMID:8980208
146. Zuccaro G Jr, **Wilson WR**, Bayer AS. Antibiotic prophylaxis for bacterial endocarditis: an evolving story with new paradigms *Arch Intern Med*. 1997; 157:130-3. PMID:8996052
147. Garau J, **Wilson WR**, Wood Martin CJ. Fourth-generation cephalosporins: a review of in vitro activity, pharmacokinetics, pharmacodynamics and clinical utility *Clin Microbiol Infect*. 1997; 3(suppl 1):S87-S101. PMID:11864121
148. Caron F, Brandt CM, Rouse M, Laue N, Stratton CW, **Wilson WR**, Steckelberg JM. Importance of using relapse studies of tests for detection of antibiotic resistance before considering that a treatment for multidrug-resistant enterococcal experimental endocarditis is effective. *J Infect Dis*. 1997; 175(1):232-233. PMID:8985229
149. Das M, Badley AD, Cockerill FR, Steckelberg JM, **Wilson WR**. Infective endocarditis caused by HACEK microorganisms. *Annu Rev Med*. 1997; 48:25-33. PMID:9046942
150. Dajani AS, Taubert KA, **Wilson WR**, Bolger AF, Bayer A, Ferrieri P, Gewitz MH, Shulman ST, Nouri S, Newburger JW, Hutto C, Pallasch TJ, Gage TW, Levison ME, Peter G, Zuccaro G. Prevention of bacterial endocarditis: recommendations by the American Heart Association *JAMA*. 1997; 277:1794-801. PMID:9178793
151. Cockerill FR 3rd, Hughes JG, Vetter EA, Mueller RA, Weaver AL, Ilstrup DM, Rosenblatt JE, **Wilson WR**. Analysis of 281,797 consecutive blood cultures performed over an eight-year period: trends in microorganisms isolated and the value of anaerobic culture of blood. *Clin Infect Dis*. 1997 Mar; 24(3):403-18. PMID:9114192
152. **Wilson WR**, Bouza E, Lode H, Mouton Y. The use of cefotaxime for the treatment of common infections: in vitro, pharmacokinetic and clinical considerations. *J Chemother*. 1997 May; 9 Suppl 2:5-18. PMID:9248972
153. Rouse MS, Steckelberg JM, Brandt CM, Patel R, Miro JM, **Wilson WR**. Efficacy of azithromycin or clarithromycin for prophylaxis of viridans group streptococcus experimental endocarditis. *Antimicrob Agents Chemother*. 1997 Aug; 41(8):1673-6. PMID:9257739 PMCID:163983
154. **Wilson WR**, Carbon C, Durack DT, Francioli P, Gutschik E, Leport C, Moreillon P, Ngu-Blackett K, Rubinstein E, Stamboulian D, Van der Meer JTM. Antibiotic treatment of infective endocarditis due to viridans streptococci, enterococci, and other streptococci. *Clin Microbiol Infect*. 1998; 4(Suppl 3):S17-S26. PMID:11869259
155. Bayer AS, Bolger AF, Taubert KA, **Wilson WR**, Steckelberg JM, Karchmer AW, Levison M, Chambers HINDFOOT, Dajani AS, Gewitz MH, Newburger JW, Gerber MA, Shulman ST, Pallasch TJ, Gage TW, Ferrieri P. Diagnosis and management of infective endocarditis and its complications *Circulation*. 1998; 98:2936-48. PMID:9860802
156. Miro JM, **Wilson WR**. Infectious complications of intravenous drug abuse. PP 11-20 in: *Atlas of Infectious Diseases* OM Korzeniowski ed, Churchill Livingstone, Philadelphia, 1998;

157. Adde M, Shad A, Venzon D, Arndt C, Gootenberg J, Neely J, Nieder M, Owen W, Seibel N, **Wilson W**, Horak ID, Magrath I. Additional chemotherapy agents improve treatment outcome for children and adults with advanced B-cell lymphomas. *Semin Oncol*. 1998 Apr; 25(2 Suppl 4):33-9; discussion 45-8. PMID:9578060
158. Cockerill FR 3rd, Thompson RL, Musser JM, Schlievert PM, Talbot J, Holley KE, Harmsen WS, Ilstrup DM, Kohner PC, Kim MH, Frankfort B, Manahan JM, Steckelberg JM, Roberson F, **Wilson WR**. Molecular, serological, and clinical features of 16 consecutive cases of invasive streptococcal disease. Southeastern Minnesota Streptococcal Working Group. *Clin Infect Dis*. 1998 Jun; 26(6):1448-58. PMID:9636878
159. Jones RN, **Wilson WR**. Epidemiology, laboratory detection, and therapy of penicillin-resistant streptococcal infections. *Diagnostic Microbiology & Infectious Disease*. 1998 Jul; 31(3):453-9. PMID:9635236
160. **Wilson WR**. The role of fourth-generation cephalosporins in the treatment of serious infectious diseases in hospitalized patients. *Diagnostic Microbiology & Infectious Disease*. 1998 Jul; 31(3):473-7. PMID:9635239
161. Sexton DJ, Tenenbaum MJ, **Wilson WR**, Steckelberg JM, Tice AD, Gilbert D, Dismukes W, Drew RH, Durack DT. Ceftriaxone once daily for four weeks compared with ceftriaxone plus gentamicin once daily for two weeks for treatment of endocarditis due to penicillin-susceptible streptococci. *Clin Infect Dis*. 1998 Dec; 27(6):1470-1474. PMID:9868662
162. Berbari EF, Jabre J, Lteif AN, Osmon DR, **Wilson WR**. Demographic characteristics of Lebanese medical graduates in the United States. *Lebanese Order of Physicians Journal*. 1999; 6:52-60. PMID:0
163. Piper KE, Rouse MS, Steckelberg JM, **Wilson WR**, Patel R. Ketolide treatment of *Haemophilus influenzae* experimental pneumonia. *Antimicrob Agents Chemother*. 1999 Mar; 43: (3)708-10. PMID:10049297 PMCID:89190
164. Patel R, Rouse MS, Florez MV, Piper KE, Cockerill FR, **Wilson WR**, Steckelberg JM. Lack of benefit of intravenous immune globulin in a murine model of group A streptococcal necrotizing fasciitis. *J Infect Dis*. 2000 Jan; 181(1):230-4. PMID:10608771 DOI:10.1086/315198
165. Piper KE, Rouse MS, Ronningen KL, Steckelberg JM, **Wilson WR**, Patel R. Trovafloxacin treatment of viridans group *Streptococcus* experimental endocarditis. *Antimicrob Agents Chemother*. 2000 Sep; 44(9):2554-6. PMID:10952616 PMCID:90106
166. Nicholson SC, **Wilson WR**, Naughton BJ, Gothelf S, Webb CD. Efficacy and safety of gatifloxacin in elderly outpatients with community-acquired pneumonia. *Diagnostic Microbiology & Infectious Disease*. 2002 Sep; 44(1):117-25. PMID:12376041
167. Nicholson SC, Webb CD, Andriole VT, Jones RN, **Wilson WR**. *Haemophilus influenzae* in respiratory tract infections in community-based clinical practice: therapy with gatifloxacin. *Diagnostic Microbiology & Infectious Disease*. 2002 Sep; 44(1):101-7. PMID:12376039
168. Levy MJ, Norton ID, Wiersema MJ, Schwartz DA, Clain JE, Vazquez-Sequeiros E, **Wilson WR**, Zinsmeister AR, Jondal ML. Prospective risk assessment of bacteremia and other infectious complications in patients undergoing EUS-guided FNA. *Gastrointest Endosc*. 2003 May; 57: (6)672-8. PMID:12709695 DOI:10.1067/mge.2003.204
169. Razonable RR, Rahman AE, **Wilson WR**. Lemierre syndrome variant: necrobacillosis associated with inferior vena cava thrombosis and pulmonary abscesses after trauma-induced leg abscess. *Mayo Clin Proc*. 2003 Sep; 78(9):1153-6. PMID:12962171 DOI:10.1016/S0025-6196(11)62941-8
170. Issa NC, Rouse MS, Piper KE, **Wilson WR**, Steckelberg JM, Patel R. In vitro activity of BAL9141 against clinical isolates of gram-negative bacteria. *Diagn Microbiol Infect Dis*. 2004 Jan; 48(1):73-5. PMID:14761726 DOI:10.1016/j.diagmicrobio.2003.09.006

171. Cockerill FR, Wilson JW, Vetter EA, Goodman KM, Torgerson CA, Harmsen WS, Schleck CD, Ilstrup DM, Washington JA, **Wilson WR**. Optimal testing parameters for blood cultures. *Clin Infect Dis*. 2004 Jun 15; 38(12):1724-30. PMID:15227618
172. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, Shulman ST, Bolger AF, Ferrieri P, Baltimore RS, **Wilson WR**, Baddour LM, Levison ME, Pallasch TJ, Falace DA, Taubert KA, Committee on Rheumatic Fever Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association, American Academy of Pediatrics. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. *Circulation*. 2004 Oct 26; 110(17):2747-71. PMID:15505111 DOI:10.1161/01.CIR.0000145143.19711.78
173. Prabhu RM, Piper KE, Baddour LM, Steckelberg JM, **Wilson WR**, Patel R. Antimicrobial susceptibility patterns among viridans group streptococcal isolates from infective endocarditis patients from 1971 to 1986 and 1994 to 2002. *Antimicrob Agents Chemother*. 2004 Nov; 48(11):4463-5. PMID:15504884 PMCID:525427 DOI:10.1128/AAC.48.11.4463-4465.2004
174. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, Shulman ST, Bolger AF, Ferrieri P, Baltimore RS, **Wilson WR**, Baddour LM, Levison ME, Pallasch TJ, Falace DA, Taubert KA, Committee on Rheumatic Fever Endocarditis and Kawasaki Disease Council on Cardiovascular Disease in the Young American Heart Association. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. *Pediatrics*. 2004 Dec; 114(6):1708-33. PMID:15574639 DOI:10.1542/peds.2004-2182
175. Baddour LM, **Wilson WR**, Bayer AS, Fowler VG Jr, Bolger AF, Levison ME, Ferrieri P, Gerber MA, Tani LY, Gewitz MH, Tong DC, Steckelberg JM, Baltimore RS, Shulman ST, Burns JC, Falace DA, Newburger JW, Pallasch TJ, Takahashi M, Taubert KA, Committee on Rheumatic Fever Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, Councils on Clinical Cardiology Stroke and Cardiovascular Surgery and Anesthesia, American Heart Association, Infectious Diseases Society of America. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. *Circulation*. 2005 Jun 14; 111(23):e394-434. PMID:15956145 DOI:10.1161/CIRCULATIONAHA.105.165564
176. Tleyjeh IM, Steckelberg JM, Murad HS, Anavekar NS, Ghomrawi HM, Mirzoyev Z, Moustafa SE, Hoskin TL, Mandrekar JN, **Wilson WR**, Baddour LM. Temporal trends in infective endocarditis: a population-based study in Olmsted County, Minnesota. *JAMA*. 2005 Jun 22; 293(24):3022-8. PMID:15972564 PMCID:0 DOI:10.1001/jama.293.24.3022
177. Sohail MR, Khan AH, Holmes DR Jr, **Wilson WR**, Steckelberg JM, Baddour LM. Infectious complications of percutaneous vascular closure devices. *Mayo Clin Proc*. 2005 Aug; 80(8):1011-5. PMID:16092579 DOI:10.4065/80.8.1011
178. Sohail MR, Martin KR, **Wilson WR**, Baddour LM, Harmsen WS, Steckelberg JM. Medical versus surgical management of Staphylococcus aureus prosthetic valve endocarditis. *Am J Med*. 2006 Feb; 119(2):147-54. PMID:0
179. Liang KP, Tleyjeh IM, **Wilson WR**, Roberts GD, Temesgen Z. Rhino-orbitocerebral mucormycosis caused by *Apophysomyces elegans*. *J Clin Microbiol*. 2006 Mar; 44(3):892-8. PMID:16517873 PMCID:1393113 DOI:10.1128/JCM.44.3.892-898.2006
180. Antonios VS, Noel AA, Steckelberg JM, **Wilson WR**, Mandrekar JN, Harmsen WS, Baddour LM. Prosthetic vascular graft infection: a risk factor analysis using a case-control study. *J Infect*. 2006 Jul; 53(1):49-55. Epub 2005 Nov 28. PMID:16310254 PMCID:0 DOI:10.1016/j.jinf.2005.10.004

181. Uslan DZ, Sohail MR, Friedman PA, Hayes DL, **Wilson WR**, Steckelberg JM, Baddour LM. Frequency of permanent pacemaker or implantable cardioverter-defibrillator infection in patients with gram-negative bacteremia. *Clin Infect Dis*. 2006 Sep 15; 43(6):731-6. Epub 2006 Aug 04. PMID:16912947 DOI:10.1086/506942
182. Cooper LT Jr, Mensah GA, Baddour LM, Dunbar SB, Kaplan EL, **Wilson WR**, Shah PK. ACCF/AHA/CDC Conference report on emerging infectious diseases and biological terrorism threats. Task Force III: prevention and control of cardiovascular complications of emerging infectious diseases and potential biological terrorism agents and diseases. *J Am Coll Cardiol*. 2007 Mar 27; 49(12):1398-406. PMID:17394981 DOI:10.1016/j.jacc.2007.01.021
183. Cooper LT Jr, Mensah GA, Baddour LM, Dunbar SB, Kaplan EL, **Wilson WR**, Shah PK. ACCF/AHA/CDC conference report on emerging infectious diseases and biological terrorism threats. Task Force III: prevention and control of cardiovascular complications of emerging infectious diseases and potential biological terrorism agents and diseases. *Circulation*. 2007 Mar 27; 115(12):1681-9. PMID:17506122
184. Mensah GA, Grant AO, Pepine CJ, Baddour LM, Cooper LT Jr, Dunbar SB, Froelicher ES, Greenlund KJ, Kaplan EL, Kloner RA, Labarthe DR, Luepker RV, Madjid M, Muller JE, O'Connor S, Ornato JP, Robertson RM, Roy MJ, Shah PK, Taubert KA, **Wilson WR**, Zheng ZJ, Harrington RA, Abrams J, Anderson JL, Bates ER, Eisenberg MJ, Grines CL, Hlatky MA, Lichtenberg RC, Lindner JR, Pohost GM, Schofield RS, Shubrooks SJ Jr, Stein JH, Tracy CM, Vogel RA, Wesley DJ. ACCF/AHA/CDC conference report on emerging infectious diseases and biological terrorism threats: the clinical and public health implications for the prevention and control of cardiovascular diseases. *J Am Coll Cardiol*. 2007 Mar 27; 49(12):1373-412. PMID:17394977 DOI:10.1016/j.jacc.2007.01.017
185. Mensah GA, Grant AO, Pepine CJ, Baddour LM, Cooper LT Jr, Dunbar SB, Froelicher ES, Greenlund KJ, Kaplan EL, Kloner RA, Labarthe DR, Luepker RV, Madjid M, Muller JE, O'Connor S, Ornato JP, Robertson RM, Roy MJ, Shah PK, Taubert KA, **Wilson WR**, Zheng ZJ, Harrington RA, Abrams J, Anderson JL, Bates ER, Eisenberg MJ, Grines CL, Hlatky MA, Lichtenberg RC, Lindner JR, Pohost GM, Schofield RS, Shubrooks SJ Jr, Stein JH, Tracy CM, Vogel RA, Wesley DJ. ACCF/AHA/CDC conference report on emerging infectious diseases and biological terrorism threats: the clinical and public health implications for the prevention and control of cardiovascular diseases. *Circulation*. 2007 Mar 27; 115(12):1656-95. Epub 2007 Mar 19. PMID:17372165 DOI:10.1161/CIRCULATIONAHA.107.181939
186. Tleyjeh IM, Ghomrawi HM, Steckelberg JM, Hoskin TL, Mirzoyev Z, Anavekar NS, Enders F, Moustafa S, Mookadam F, Huskins WC, **Wilson WR**, Baddour LM. The impact of valve surgery on 6-month mortality in left-sided infective endocarditis. *Circulation*. 2007 Apr 3; 115(13):1721-8. Epub 2007 Mar 19. PMID:17372170 DOI:10.1161/CIRCULATIONAHA.106.658831
187. Uslan DZ, Sohail MR, St Sauver JL, Friedman PA, Hayes DL, Stoner SM, **Wilson WR**, Steckelberg JM, Baddour LM. Permanent pacemaker and implantable cardioverter defibrillator infection: a population-based study. *Arch Intern Med*. 2007 Apr 9; 167(7):669-75. PMID:17420425
188. Uslan DZ, Crane SJ, Steckelberg JM, Cockerill FR 3rd, St Sauver JL, **Wilson WR**, Baddour LM. Age- and sex-associated trends in bloodstream infection: a population-based study in Olmsted County, Minnesota. *Arch Intern Med*. 2007 Apr 23; 167(8):834-9. PMID:17452548
189. Anavekar NS, Tleyjeh IM, Anavekar NS, Mirzoyev Z, Steckelberg JM, Haddad C, Khandaker MH, **Wilson WR**, Chandrasekaran K, Baddour LM. Impact of prior antiplatelet therapy on risk of embolism in infective endocarditis. *Clin Infect Dis*. 2007 May 1; 44(9):1180-6. Epub 2007 Mar 14. PMID:17407036 DOI:10.1086/513197
190. Moreillon P, **Wilson WR**, Leclercq R, Entenza JM. Single-dose oral amoxicillin or linezolid for prophylaxis of experimental endocarditis due to vancomycin-susceptible and vancomycin-resistant *Enterococcus faecalis*. *Antimicrob Agents Chemother*. 2007 May; 51(5):1661-5. Epub 2007 Mar 12. PMID:17353251 PMID:1855552 DOI:10.1128/AAC.00744-06

191. Sohail MR, Uslan DZ, Khan AH, Friedman PA, Hayes DL, **Wilson WR**, Steckelberg JM, Stoner S, Baddour LM. Management and outcome of permanent pacemaker and implantable cardioverter-defibrillator infections. *J Am Coll Cardiol*. 2007 May 8; 49(18):1851-9. PMID:17481444
192. **Wilson W**, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, Bolger A, Cabell CH, Takahashi M, Baltimore RS, Newburger JW, Strom BL, Tani LY, Gerber M, Bonow RO, Pallasch T, Shulman ST, Rowley AH, Burns JC, Ferrieri P, Gardner T, Goff D, Durack DT, American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, Quality of Care and Outcomes Research Interdisciplinary Working Group, American Dental Association. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. *J Am Dent Assoc*. 2007 Jun; 138(6):739-45, 747-60. PMID:17545263
193. Levy MJ, Norton ID, Clain JE, Enders FB, Gleeson F, Limburg PJ, Nelson H, Rajan E, Topazian MD, Wang KK, Wiersema MJ, **Wilson WR**. Prospective Study of Bacteremia and Complications With EUS FNA of Rectal and Perirectal Lesions. *Clin Gastroenterol Hepatol*. 2007 Jun; 5(6):684-9. PMID:17544995
194. Knoll B, Tleyjeh IM, Steckelberg JM, **Wilson WR**, Baddour LM. Infective endocarditis due to penicillin-resistant viridans group streptococci. *Clin Infect Dis*. 2007 Jun 15; 44(12):1585-92. PMID:17516402
195. Sohail MR, Uslan DZ, Khan AH, Friedman PA, Hayes DL, **Wilson WR**, Steckelberg JM, Stoner SM, Baddour LM. Risk factor analysis of permanent pacemaker infection. *Clin Infect Dis*. 2007 Jul 15; 45(2):166-73. Epub 2007 Jun 06. PMID:17578774 DOI:10.1086/518889
196. Tleyjeh IM, Abdel-Latif A, Rahbi H, Scott CG, Bailey KR, Steckelberg JM, **Wilson WR**, Baddour LM. A systematic review of population-based studies of infective endocarditis. *Chest*. 2007 Sep; 132(3):1025-35. PMID:17873196 DOI:10.1378/chest.06-2048
197. **Wilson W**, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, Bolger A, Cabell CH, Takahashi M, Baltimore RS, Newburger JW, Strom BL, Tani LY, Gerber M, Bonow RO, Pallasch T, Shulman ST, Rowley AH, Burns JC, Ferrieri P, Gardner T, Goff D, Durack DT, American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee//American Heart Association Council on Cardiovascular Disease in the Young//American Heart Association Council on Clinical Cardiology//American Heart Association Council on Cardiovascular Surgery and Anesthesi. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. *Circulation*. 2007 Oct 9; 116: (15)1736-54. PMID:17446442 DOI:10.1161/CIRCULATIONAHA.106.183095
198. Sohail MR, Uslan DZ, Khan AH, Friedman PA, Hayes DL, **Wilson WR**, Steckelberg JM, Jenkins SM, Baddour LM. Infective endocarditis complicating permanent pacemaker and implantable cardioverter-defibrillator infection. *Mayo Clin Proc*. 2008 Jan; 83(1):46-53. PMID:18174000
199. **Wilson W**, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, Bolger A, Cabell CH, Takahashi M, Baltimore RS, Newburger JW, Strom BL, Tani LY, Gerber M, Bonow RO, Pallasch T, Shulman ST, Rowley AH, Burns JC, Ferrieri P, Gardner T, Goff D, Durack DT, American Heart Association. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. *J Am Dent Assoc*. 2008 Jan; 139 Suppl:3S-24S. PMID:18167394

200. Hoelzer BC, Weingarten TN, Hooten WM, Wright RS, **Wilson WR**, Wilson PR. Paraspinal abscess complicated by endocarditis following a facet joint injection. *Eur J Pain*. 2008 Apr; 12(3):261-5. Epub 2007 Jul 02. PMID:17606390 DOI:10.1016/j.ejpain.2007.05.005
201. Tleyjeh IM, Steckelberg JM, Georgescu G, Ghomrawi HM, Hoskin TL, Enders FB, Mookadam F, Huskins WC, **Wilson WR**, Baddour LM. The association between the timing of valve surgery and 6-month mortality in left-sided infective endocarditis. *Heart*. 2008 Jul; 94(7):892-6. Epub 2008 Feb 28. PMID:18308866 DOI:10.1136/hrt.2007.118968
202. Tleyjeh IM, Kashour T, Zimmerman V, Steckelberg JM, **Wilson WR**, Baddour LM. The role of valve surgery in infective endocarditis management: a systematic review of observational studies that included propensity score analysis. *Am Heart J*. 2008 Nov; 156(5):901-9. Epub 2008 Sep 11. PMID:19061705 DOI:10.1016/j.ahj.2008.06.031
203. Fadel HJ, Tleyjeh IM, Steckelberg JM, **Wilson WR**, Baddour LM. Evaluation of antibiotic therapy following valve replacement for native valve endocarditis. *Eur J Clin Microbiol Infect Dis*. 2009 Nov; 28 (11):1395-8 Epub 2009 Aug 25 PMID:19705174 DOI:10.1007/s10096-009-0784-7
204. Berbari EF, Osmon DR, Carr A, Hanssen AD, Baddour LM, Greene D, Kupp LI, Baughan LW, Harmsen WS, Mandrekar JN, Therneau TM, Steckelberg JM, Virk A, **Wilson WR**. Dental procedures as risk factors for prosthetic hip or knee infection: a hospital-based prospective case-control study. *Clin Infect Dis*. 2010 Jan 1; 50(1):8-16. PMID:19951109 DOI:10.1086/648676
205. Noheria A, Anderson PW, Tapia-Zegarra GG, Baddour LM, **Wilson WR**. Infective endocarditis due to neisseria elongata. *IDCP*. 2010; 18(6):355-8.
206. Sia IG, Orillaza RB, St Sauver JL, Quelapio ID, Lahr BD, Alcaneses RS, **Wilson WR**, Cockerill FR, Balane GI, Mangubat NV, Wengenack NL, Tupasi TE. Tuberculosis attributed to household contacts in the Philippines. *Int J Tuberc Lung Dis*. 2010 Jan; 14(1):122-5. PMID:20003706
207. Baddour LM, Epstein AE, Erickson CC, Knight BP, Levison ME, Lockhart PB, Masoudi FA, Okum EJ, **Wilson WR**, Beerman LB, Bolger AF, Estes NA 3rd, Gewitz MH, Newburger JW, Schron EB, Taubert KA, American Heart Association Rheumatic Fever Endocarditis, Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young Council on Cardiovascular Surgery, Anesthesia, Council on Cardiovascular Nursing, Council on Clinical Cardiology, Interdisciplinary Council on Quality of Care, American Heart Association. Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. *Circulation*. 2010 Jan 26; 121(3):458-77.
208. Tleyjeh IM, Ghomrawi HM, Steckelberg JM, Montori VM, Hoskin TL, Enders F, Huskins WC, Mookadam F, **Wilson WR**, Zimmerman V, Baddour LM. Conclusion about the association between valve surgery and mortality in an infective endocarditis cohort changed after adjusting for survivor bias. *J Clin Epidemiol*. 2010 Feb; 63(2):130-5. PMID:20122499 DOI:10.1016/j.jclinepi.2008.06.022
209. Tleyjeh IM, Ghomrawi HM, Steckelberg JM, Montori VM, Hoskin TL, Enders F, Huskins WC, Mookadam F, **Wilson WR**, Zimmerman V, Baddour LM. Propensity score analysis with a time-dependent intervention is an acceptable although not an optimal analytical approach when treatment selection bias and survivor bias coexist. *J Clin Epidemiol*. 2010 Feb; 63(2):139-40. Epub 2009 Nov 12. PMID:19913387 DOI:10.1016/j.jclinepi.2009.07.017
210. Uslan DZ, Dowsley TF, Sohail MR, Hayes DL, Friedman PA, **Wilson WR**, Steckelberg JM, Baddour LM. Cardiovascular implantable electronic device infection in patients with Staphylococcus aureus bacteremia. *Pacing Clin Electrophysiol*. 2010 Apr; 33(4):407-13. Epub 2009 Sep 30. PMID:19793360 DOI:10.1111/j.1540-8159.2009.02565.x

211. Correa de Sa DD, Tleyjeh IM, Anavekar NS, Schultz JC, Thomas JM, Lahr BD, Bachuwar A, Pazdernik M, Steckelberg JM, **Wilson WR**, Baddour LM. Epidemiological trends of infective endocarditis: a population-based study in Olmsted County, Minnesota. *Mayo Clin Proc.* 2010 May; 85: (5)422-6. PMID:20435834 PMCID:2861970 DOI:10.4065/mcp.2009.0585
212. Shah NB, Suri RM, Melduni RM, Patel R, Kommedal O, Saebo O, Gustafson DR, **Wilson WR**, Baddour LM. *Shuttleworthia* satellites endocarditis: evidence of non-dental human disease. *J Infect.* 2010 Jun; 60(6):491-3. Epub 2010 Feb 17. PMID:20170673 DOI:10.1016/j.jinf.2010.02.008
213. El Helou OC, Berbari EF, Lahr BD, Eckel-Passow JE, Razonable RR, Sia IG, Virk A, Walker RC, Steckelberg JM, **Wilson WR**, Hanssen AD, Osmon DR. Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention. *Eur J Clin Microbiol Infect Dis.* 2010 Aug; 29 (8):961-7 Epub 2010 May 27 PMID:20505968 DOI:10.1007/s10096-010-0952-9
214. Madhavan M, Sohail MR, Friedman PA, Hayes DL, Steckelberg JM, **Wilson WR**, Baddour LM, Mayo Cardiovascular Infections Study Group. Outcomes in patients with cardiovascular implantable electronic devices and bacteremia caused by Gram-positive cocci other than *Staphylococcus aureus*. *Circ Arrhythm Electrophysiol.* 2010 Dec; 3(6):639-45. Epub 2010 Sep 18. PMID:20852296 DOI:10.1161/CIRCEP.110.957514
215. Baddour LM, Epstein AE, Erickson CC, Knight BP, Levison ME, Lockhart PB, Masoudi FA, Okum EJ, **Wilson WR**, Beerman LB, Bolger AF, Estes NA 3rd, Gewitz M, Newburger JW, Schron EB, Taubert KA, American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, Council on Cardiovascular Surgery and Anesthesia, Council on Cardiovascular Nursing, Council on Clinical Cardiology, Interdisciplinary Council on Quality of Care and Outcomes Research. A summary of the update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. *J Am Dent Assoc.* 2011 Feb; 142(2):159-65. PMID:21282681
216. LE KY, Sohail MR, Friedman PA, Uslan DZ, Cha SS, Hayes DL, **Wilson WR**, Steckelberg JM, Baddour LM, Mayo Cardiovascular Infections Study Group. Clinical predictors of cardiovascular implantable electronic device-related infective endocarditis. *Pacing Clin Electrophysiol.* 2011 Apr; 34: (4)450-9. PMID:21208230 DOI:10.1111/j.1540-8159.2010.02991.x
217. Boland JM, Chung HH, Robberts FJ, **Wilson WR**, Steckelberg JM, Baddour LM, Miller DV. Fungal prosthetic valve endocarditis: Mayo Clinic experience with a clinicopathological analysis. *Mycoses.* 2011 Jul; 54(4):354-60. Epub 2010 Apr 06. PMID:20406395 DOI:10.1111/j.1439-0507.2010.01884.x
218. Sohail MR, Hussain S, Le KY, Dib C, Lohse CM, Friedman PA, Hayes DL, Uslan DZ, **Wilson WR**, Steckelberg JM, Baddour LM, Mayo Cardiovascular Infections Study Group. Risk factors associated with early- versus late-onset implantable cardioverter-defibrillator infections. *J Interv Card Electrophysiol.* 2011 Aug; 31: (2)171-83. PMID:21365264 DOI:10.1007/s10840-010-9537-x
219. Steckelberg RC, Wang AT, **Wilson W**. Infective endophthalmitis due to Group G Streptococcal infection in a patient with metastatic ovarian carcinoma. *BMJ Case Rep.* 2011 Aug 19; 2011: PMID:22678738 PMCID:3171054 DOI:10.1136/bcr.07.2011.4526
220. Le KY, Sohail MR, Friedman PA, Uslan DZ, Cha SS, Hayes DL, **Wilson WR**, Steckelberg JM, Baddour LM, Mayo Cardiovascular Infections Study Group. Impact of timing of device removal on mortality in patients with cardiovascular implantable electronic device infections. *Heart Rhythm.* 2011 Nov; 8: (11)1678-85. PMID:21699855 DOI:10.1016/j.hrthm.2011.05.015
221. Anavekar NS, Schultz JC, De Sa DD, Thomas JM, Lahr BD, Tleyjeh IM, Steckelberg JM, **Wilson WR**, Baddour LM. Modifiers of symptomatic embolic risk in infective endocarditis. *Mayo Clin Proc.* 2011 Nov; 86(11):1068-74. PMID:22033251 PMCID:3202997 DOI:10.4065/mcp.2011.0111

222. Lockhart PB, Bolger AF, Papapanou PN, Osinbowale O, Trevisan M, Levison ME, Taubert KA, Newburger JW, Gornik HL, Gewitz MH, **Wilson WR**, Smith SC Jr, Baddour LM, American Heart Association Rheumatic Fever Endocarditis and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young Council on Epidemiology and Prevention Council on Peripheral Vascular Disease and Council on Clinical Cardiol. Periodontal disease and atherosclerotic vascular disease: does the evidence support an independent association?: a scientific statement from the American Heart Association. *Circulation*. 2012 May 22; 125(20):2520-44. Epub 2012 Apr 18 PMID:22514251 DOI:10.1161/CIR.0b013e31825719f3
223. Desimone DC, Tleyjeh IM, Correa de Sa DD, Anavekar NS, Lahr BD, Sohail MR, Steckelberg JM, **Wilson WR**, Baddour LM, Mayo Cardiovascular Infections Study Group. Incidence of infective endocarditis caused by viridans group streptococci before and after publication of the 2007 American Heart Association's endocarditis prevention guidelines. *Circulation*. 2012 Jul 3; 126:(1)60-4. PMID:22689929 PMCID:3681201 DOI:10.1161/CIRCULATIONAHA.112.095281
224. Baddour LM, Cha YM, **Wilson WR**. Clinical practice. Infections of cardiovascular implantable electronic devices. *N Engl J Med*. 2012 Aug 30; 367(9):842-9. PMID:22931318 DOI:10.1056/NEJMcp1107675
225. Le KY, Sohail MR, Friedman PA, Uslan DZ, Cha SS, Hayes DL, **Wilson WR**, Steckelberg JM, Baddour LM, Mayo Cardiovascular Infections Study Group. Clinical features and outcomes of cardiovascular implantable electronic device infections due to staphylococcal species. *Am J Cardiol*. 2012 Oct 15; 110(8):1143-9. Epub 2012 Jul 03. PMID:22762715 DOI:10.1016/j.amjcard.2012.05.052
226. Sohail MR, Hussain S, Le KY, Dib C, Lohse CM, Friedman PA, Hayes DL, Uslan DZ, **Wilson WR**, Steckelberg JM, Baddour LM, for the Mayo Cardiovascular Infections Study Group. Erratum to: Risk factors associated with early- versus late-onset implantable cardioverter-defibrillator infections. *J Interv Card Electrophysiol*. 2012 Dec; 35(3):355. PMID:23080325 DOI:10.1007/s10840-012-9730-1
227. Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM, Rao N, Hanssen A, **Wilson WR**, Infectious Diseases Society of America. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. *Clin Infect Dis*. 2013 Jan; 56(1):e1-e25. Epub 2012 Dec 6 PMID:23223583 DOI:10.1093/cid/cis803
228. DeSimone DC, Baddour LM, Lahr BD, Chung HH, **Wilson WR**, Steckelberg JM, Mayo Cardiovascular Infections Study Group. Euthermic endocarditis. *PLoS One*. 2013; 8(11):e80144. Epub 2013 Nov 11. PMID:24244630 PMCID:3823819 DOI:10.1371/journal.pone.0080144
229. Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM, Rao N, Hanssen A, **Wilson WR**, Infectious Diseases Society of America. Executive summary: diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. *Clin Infect Dis*. 2013 Jan; 56(1):1-10. PMID:23230301 DOI:10.1093/cid/cis966
230. Habib A, Irfan M, Baddour LM, Le KY, Anavekar NS, Lohse CM, Friedman PA, Hayes DL, **Wilson WR**, Steckelberg JM, Sohail MR. Impact of prior aspirin therapy on clinical manifestations of cardiovascular implantable electronic device infections. *Europace*. 2013 Feb; 15(2):227-35. Epub 2012 Sep 05. PMID:22956593 DOI:10.1093/europace/eus292
231. Coelho-Prabhu N, Oxentenko AS, Osmon DR, Baron TH, Hanssen AD, **Wilson WR**, Steckelberg JM, Baddour LM, Harmsen WS, Mandrekar J, Berbari EF. Increased risk of prosthetic joint infection associated with esophago-gastro-duodenoscopy with biopsy. *Acta Orthop*. 2013 Feb; 84(1):82-6. Epub 2013 Jan 25. PMID:23350577 PMCID:3584609 DOI:10.3109/17453674.2013.769079
232. Habib A, Le KY, Baddour LM, Friedman PA, Hayes DL, Lohse CM, **Wilson WR**, Steckelberg JM, Sohail MR, Mayo Cardiovascular Infections Study Group. Predictors of mortality in patients with cardiovascular implantable electronic device infections. *Am J Cardiol*. 2013 Mar 15; 111(6):874-9. Epub 2012 Dec 29 PMID:23276467 DOI:10.1016/j.amjcard.2012.11.052

233. Hickson LJ, Gooden JY, Le KY, Baddour LM, Friedman PA, Hayes DL, **Wilson WR**, Steckelberg JM, Sohail MR. Clinical presentation and outcomes of cardiovascular implantable electronic device infections in hemodialysis patients. *Am J Kidney Dis*. 2014 Jul; 64: (1)104-10. PMID:24388672 PMID:4069232 DOI:10.1053/j.ajkd.2013.11.018
234. Vasoo S, Mason EL, Gustafson DR, Cunningham SA, Cole NC, Vetter EA, Steinmann SP, **Wilson WR**, Patel R, Barbari EF, Henry NK. *Desulfovibrio legallii* prosthetic shoulder joint infection and review of antimicrobial susceptibility and clinical characteristics of *Desulfovibrio* infections. *J Clin Microbiol*. 2014 Aug; 52: (8)3105-10. PMID:24850351 PMID:4136176 DOI:10.1128/JCM.00083-14
235. Kebed KY, Bishu K, Al Adham RI, Baddour LM, Connolly HM, Sohail MR, Steckelberg JM, **Wilson WR**, Murad MH, Anavekar NS. Pregnancy and postpartum infective endocarditis: a systematic review. *Mayo Clin Proc*. 2014 Aug; 89(8):1143-52. Epub 2014 Jul 01. PMID:24997091 DOI:10.1016/j.mayocp.2014.04.024
236. Sohail MR, Palraj BR, Khalid S, Uslan DZ, Al-Saffar F, Friedman PA, Hayes DL, Lohse CM, **Wilson WR**, Steckelberg JM, Baddour LM. Predicting risk of endovascular device infection in patients with *Staphylococcus aureus* bacteremia (PREDICT-SAB). *Circ Arrhythm Electrophysiol*. 2015 Feb; 8: (1)137-44. PMID:25504648 PMID:4334722 DOI:10.1161/CIRCEP.114.002199
237. DeSimone DC, Tleyjeh IM, Correa de Sa DD, Anavekar NS, Lahr BD, Sohail MR, Steckelberg JM, **Wilson WR**, Baddour LM, Mayo Cardiovascular Infections Study Group. Incidence of Infective Endocarditis Due to Viridans Group Streptococci Before and After the 2007 American Heart Association's Prevention Guidelines: An Extended Evaluation of the Olmsted County, Minnesota, Population and Nationwide Inpatient Sample. *Mayo Clin Proc*. 2015 Jul; 90: (7)874-81. PMID:26141329 PMID:4560595 DOI:10.1016/j.mayocp.2015.04.019
238. Palraj BR, Baddour LM, Hess EP, Steckelberg JM, **Wilson WR**, Lahr BD, Sohail MR. Predicting Risk of Endocarditis Using a Clinical Tool (PREDICT): Scoring System to Guide Use of Echocardiography in the Management of *Staphylococcus aureus* Bacteremia. *Clin Infect Dis*. 2015 Jul 01; 61: (1)18-28. PMID:25810284 PMID:4542912 DOI:10.1093/cid/civ235
239. DeSimone DC, DeSimone CV, Tleyjeh IM, Correa de Sa DD, Anavekar NS, Lahr BD, Sohail MR, Steckelberg JM, **Wilson WR**, Baddour LM. Association of Mitral Valve Prolapse With Infective Endocarditis Due to Viridans Group Streptococci. *Clin Infect Dis*. 2015 Aug 15; 61: (4)623-5. PMID:25963288 PMID:4542600 DOI:10.1093/cid/civ375
240. Gupta A, Osmon DR, Hanssen AD, Lightner DJ, **Wilson WR**, Steckelberg JM, Baddour LM, Harmsen WS, Mandrekar JN, Barbari EF. Genitourinary Procedures as Risk Factors for Prosthetic Hip or Knee Infection: A Hospital-Based Prospective Case-Control Study. *Open Forum Infect Dis*. 2015 Sep; 2: (3)ofv097. PMID:26258154 PMID:4525011 DOI:10.1093/ofid/ofv097
241. DeSimone DC, Tleyjeh IM, Correa de Sa DD, Anavekar NS, Lahr BD, Sohail MR, Steckelberg JM, **Wilson WR**, Baddour LM. Temporal trends in infective endocarditis epidemiology from 2007 to 2013 in Olmsted County, MN. *Am Heart J*. 2015 Oct; 170: (4)830-6. PMID:26386808 PMID:4677064 DOI:10.1016/j.ahj.2015.07.007
242. Miranda WR, Connolly HM, DeSimone DC, Phillips SD, **Wilson WR**, Sohail MR, Steckelberg JM, Baddour LM. Infective Endocarditis Involving the Pulmonary Valve. *Am J Cardiol*. 2015 Dec 15; 116: (12)1928-31. PMID:26611123 DOI:10.1016/j.amjcard.2015.09.038
243. El Rafei A, DeSimone DC, DeSimone CV, Lahr BD, Steckelberg JM, Sohail MR, **Wilson WR**, Baddour LM. Beta-haemolytic streptococcal endocarditis: clinical presentation, management and outcomes. *Infect Dis (Lond)*. 2016; 48: (5)373-8. PMID:26950685
244. Tande AJ, Palraj BR, Osmon DR, Barbari EF, Baddour LM, Lohse CM, Steckelberg JM, **Wilson WR**, Sohail MR. Clinical Presentation, Risk Factors, and Outcomes of Hematogenous Prosthetic Joint Infection in Patients with *Staphylococcus aureus* Bacteremia. *Am J Med*. 2016 Feb; 129: (2)221.e11-20. PMID:26453989 DOI:10.1016/j.amjmed.2015.09.006

245. El Rafei A, Desimone DC, Sohail MR, Desimone CV, Steckelberg JM, **Wilson WR**, Baddour LM. Cardiovascular Implantable Electronic Device Infections due to Propionibacterium Species. *Pacing Clin Electrophysiol*. 2016 Jun; 39: (6)522-30. PMID:26970081 PMCID:4889492 DOI:10.1111/pace.12845
246. Miranda WR, Connolly HM, Bonnicksen CR, DeSimone DC, Dearani JA, Maleszewski JJ, Greason KL, **Wilson WR**, Baddour LM. Prosthetic pulmonary valve and pulmonary conduit endocarditis: clinical, microbiological and echocardiographic features in adults. *Eur Heart J Cardiovasc Imaging*. 2016 Aug; 17: (8)936-43. PMID:27161836 DOI:10.1093/ehjci/jew086
247. Mesa RA, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, Ma X, **Wilson W**, Paranagama DC, Dubinski DG, Naim A, Parasuraman S, Boyle J, Mascarenhas JO. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey. *Cancer*. 2017 Feb 01; 123: (3)449-458. PMID:27690182 PMCID:5297986 DOI:10.1002/cncr.30325
248. DeSimone DC, El Rafei A, Challener DW, Carr AB, Kelly JA, Rocca WA, St Sauver JL, Bock-Goodner CM, Lahr BD, Steckelberg JM, **Wilson WR**, Baddour LM. Effect of the American Heart Association 2007 Guidelines on the Practice of Dental Prophylaxis for the Prevention of Infective Endocarditis in Olmsted County, Minnesota. *Mayo Clin Proc*. 2017 May 10 [Epub ahead of print] PMID:28549764 DOI:10.1016/j.mayocp.2017.03.013
249. Tan EM, DeSimone DC, Sohail MR, Baddour LM, **Wilson WR**, Steckelberg JM, Virk A. Outcomes in Patients With Cardiovascular Implantable Electronic Device Infection Managed With Chronic Antibiotic Suppression. *Clin Infect Dis*. 2017 Jun 01; 64: (11)1516-1521. PMID:28329125 DOI:10.1093/cid/cix181
250. Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, **Wilson W**, Seymour JF, Kelly K, Gribben J, Pfreunschuh M, Morschhauser F, Schoder H, Zelenetz AD, Rademaker J, Advani R, Valente N, Fortpied C, Witzig TE, Sehn LH, Engert A, Fisher RI, Zinzani PL, Federico M, Hutchings M, Bollard C, Trneny M, Elsayed YA, Tobinai K, Abramson JS, Fowler N, Goy A, Smith M, Ansell S, Kuruvilla J, Dreyling M, Thieblemont C, Little RF, Aurer I, Van Oers MHJ, Takeshita K, Gopal A, Rule S, de Vos S, Kloos I, Kaminski MS, Meignan M, Schwartz LH, Leonard JP, Schuster SJ, Seshan VE. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). *Ann Oncol*. 2017 Jul 01; 28 (7):1436-1447 PMID:28379322 DOI:10.1093/annonc/mdx097
251. Tan EM, Nagpal A, DeSimone DC, Anderson B, Linderbaum J, De Ziel T, Li Z, Sohail MR, Cha YM, Loomis E, Espinosa R, Friedman PA, Greason K, Schiller H, Virk A, **Wilson WR**, Steckelberg JM, Baddour LM. Impacts of a care process model and inpatient electrophysiology service on cardiovascular implantable electronic device infections: a preliminary evaluation. *J Interv Card Electrophysiol*. 2017 Aug 26 [Epub ahead of print] PMID:28844107 DOI:10.1007/s10840-017-0282-2
252. Tissot-Dupont H, Casalta JP, Gouriet F, Hubert S, Salaun E, Habib G, Fernandez-Gerlinger MP, Mainardi JL, Tattevin P, Revest M, Lucht F, Botelho-Nevers E, Gagneux-Brunon A, Snygg-Martin U, Chan KL, Bishara J, Vilacosta I, Olmos C, San Roman JA, Lopez J, Tornos P, Fernandez-Hidalgo N, Durante-Mangoni E, Utili R, Paul M, Baddour LM, DeSimone DC, Sohail MR, Steckelberg JM, **Wilson WR**, Raoult D. International experts' practice in the antibiotic therapy of infective endocarditis is not following the guidelines. *Clin Microbiol Infect*. 2017 Oct; 23 (10):736-739 Epub 2017 Mar 18 PMID:28323194 DOI:10.1016/j.cmi.2017.03.007
253. Chakraborty T, Scharf E, Rabinstein AA, DeSimone D, El Rafei A, Brinjikji W, Baddour LM, Wijidicks E, **Wilson W**, Steckelberg JM, Fugate JE. Utility of Brain Magnetic Resonance Imaging in the Surgical Management of Infective Endocarditis. *J Stroke Cerebrovasc Dis*. 2017 Nov; 26 (11):2527-2535 Epub 2017 June 30 PMID:28673812 DOI:10.1016/j.jstrokecerebrovasdis.2017.05.047

Books

1. Bartlett JG, Ryan KJ, Smith TF, **Wilson WR**, Washington JA II. Cumitech 7a: laboratory diagnosis of lower respiratory tract infections. Washington, DC: American Society for Microbiology; 1987 Sep.
2. Steckelberg JM, **Wilson WR**. Infectious Disease Clinics of North America. Steckelberg JM, Wilson WR, Editors. Philadelphia: W.B. Saunders Company, 1993.
3. **Wilson WR**, Sande MA. Current Diagnosis and Treatment in Infectious Diseases. New York: Lange Medical Books/McGraw-Hill; 2001. 987 P.

Book Chapters

1. Wilkowske CJ, Wellman WE, Brewer NS, Hermans PE, Thompson RL, Van Scoy RE, **Wilson WR**. Clinical use of antimicrobial agents. In: Kelly VC, editor. Practice of Peds. Volume 2. Harper & Row; 1977. (chapter 2) p. 1-37.
2. **Wilson WR**. Prosthetic valve endocarditis: incidence, anatomic location, cause, morbidity, mortality. In: Duma RJ, editor. Infections of Prosthetic Heart Valves and Vascular Grafts. Baltimore: Univ. Park Press; 1977. p. 3-16.
3. **Wilson WR**. Sepsis: definitions, underlying conditions, manifestations. In: Washington JA II, editor. The Detection of Septicemia. Cleveland, OH: CRC Press; 1978. p. 1-21.
4. Hermans PE, **Wilson WR**. Immunoglobulin deficiency-pathogenesis and types of infection. In: Verhoef J, et al, editors. Infections in the Immunocompromised Host--- Pathogenesis, Prevention and Therapy. Elsevier: North-Holland Biomedical Press; 1980. p. 5-20.
5. **Wilson WR**, Geraci JE. Antimicrobial therapy for penicillin-sensitive streptococcal infective endocarditis: two week regimen. PP 61-73 in: Treatment of Infective Endocarditis. A. L. Bisno, ed., Grune and Stratton, New York, 1981.
6. **Wilson WR**, Geraci JE. Infective endocarditis. PP 213-220 in: Current Therapy. H. F. Conn, ed., W. B. Saunders Company, Philadelphia, 1981.
7. **Wilson WR**, Lie JT, Houser OW, Piepgras DG, Geraci JE. The management of patients with mycotic aneurysm. In: Remington JS, Swartz MN, editors. Current Clinical Topics in Infectious Diseases-2. New York: McGraw-Hill; 1981. p. 151-83.
8. **Wilson WR**, Geraci JE. Anaerobic infections of the cardiovascular system. In: Finegold SM, editor. First United States Metronidazole Conference. New York: Biomedical Information Corp.; 1982. p. 279-84.
9. **Wilson WR**, Geraci JE. Infective endocarditis-new concepts in therapy. PP 171-178, in: The Management of Infectious Diseases in Clinical Practice. P. K. Peterson and L. D. Sabath, eds., Academic Press, Inc., New York, 1982.
10. **Wilson WR**. Toxic shock syndrome and kawasaki syndrome. PP 255-260, in: The Management of Infectious Diseases in Clinical Practice. P. K. Peterson and L. D. Sabath, eds. New York: Academic Press, Inc., 1982.
11. **Wilson WR**, Geraci JE. Brucella, Francisella tularensis, Pasteurella, and Yersinia. In: Stein JH, editor. Internal Medicine. Boston, MA: Little, Brown and co.; 1983. p. 1377-85.

12. Harris RL, **Wilson WR**, Williams TW Jr. Infections associated with prosthetic heart valves. In: Sugarman B, Young EJ, editors. *Infections Associated with Prosthetic Devices*. Boca Raton, FL: CRC Press, Inc.; 1984. p. 89-112.
13. **Wilson WR**, Geraci JE. Treatment of penicillin-sensitive streptococcal endocarditis. 101-12 in: *Contemporary Issues in Infectious Diseases*, Vol. 2. M.A. Sande, D. Kaye, R.K. Root, eds., Churchill Livingstone, New York, 1984.
14. Washington JA II, **Wilson WR**. Collection and handling of specimens. In: Washington JA II, editor. *Laboratory Procedures in Clinical Microbiology*. Second Edition. New York: Springer-Verlag; 1985. p. 1-69.
15. **Wilson WR**. Experimental streptococcal endocarditis in rabbits. PP 75-76 in: *Recent Advances in Chemotherapy*. Proceedings of the 14th International Congress of Chemotherapy, Kyoto. Joji Ishigami, Ed., University of Tokyo Press, 1985.
16. **Wilson WR**. Antimicrobial therapy of infective endocarditis. 420-35 in: *The Antimicrobial Agents Annual I*. P. K. Peterson and J. Verhoef, eds., Elsevier Science Publishers BV, The Netherlands, 1986.
17. Gephart JF, Backes RJ, **Wilson WR**. Nutritionally variant streptococci. In: Magilligan Jr. DJ, Quinn EL, editors. *Endocarditis: Medical and Surgical Management*. New York: Marcel Dekker, Inc.; 1986. p. 77-84.
18. Prakash UBS, **Wilson WR**. Pneumonias caused by bacteria. Chpt 23, pp 1-35 in: *Clinical Medicine*. J. A. Spittel, Jr., Ed., Harper & Row Publishers, Philadelphia, Volume 2, 1986.
19. Prakash UBS, **Wilson WR**. Pneumonias caused by bacteria. In: Neu HC, editor. *Clinical Medicine*. Vol. 2. *Infectious Diseases*. Volume 2. Hagerstown, Maryland: Harper & Row; 1986. (chapter 23) p. 1-35.
20. Backes RJ, **Wilson WR**, Geraci JE. *Streptococcus bovis*. In: Magilligan DJ Jr., Quinn EL, editors. *Endocarditis: Medical and Surgical Management*. New York: Marcel Dekker, Inc.; 1986. p. 37-47.
21. **Wilson WR**, Geraci JE. Infections caused by *Brucella*, *Francisella tularensis*, *Pasteurella*, and *Yersinia*. In: Stein JH, editor. *Internal Medicine*. 2nd Edition. Boston: Little, Brown and Company; 1987. p. 1696-705.
22. **Wilson WR**, Geraci JE, Giuliani ER. Infective endocarditis. In: Brandenburg RO, Fuster V, Giuliani ER, McGoon DC, with contributors, editors. *Cardiology: Fundamentals and Practice*. Chicago: Year Book Med. Publ. Inc.; 1987. p. 1504-39.
23. Henry NK, **Wilson WR**. Prosthetic valve endocarditis. In: Starek PJK, editor. *Heart Valve Replacement and Reconstruction: Clinical Issues and Trends*. Chicago: Year Book Medical Publ., Inc.; 1987. p. 305-15.
24. **Wilson WR**. Enterococcal endocarditis. Ch 1, pp 15-18 in: *Challenges in Gram-Positive Infection: A Global Perspective-The enterococcus*. R. C. Moellering, Jr., ed., Healthmark, New York, 1988
25. **Wilson WR**. Imipenem/cilastatin versus antibiotic combination in therapy of septicemia. PP 23-24, in: *Therapeutic Progress with Carbapenem-Antibiotics in Serious Infections*. H. Lode and E. H. Kass, eds., Georg Thieme Verlag Stuttgart, New York, 1988
26. Paya CV, **Wilson WR**, Fitzgerald R. Management of infection in total knee arthroplasty. In: Remington J, Swartz M, editors. *Current Clinical Topics in Infectious Diseases*. Volume 9. New York: McGraw Hill; 1988. p. 222.

27. **Wilson WR**. Treatment of infective endocarditis in intensive care unit patients. PP 77-85, in: Infection in Critical Care Units. A. Net Castel, ed., Ediciones Doyma, S.A., Barcelona, Spain, 1988
28. Dorsher CW, **Wilson WR**, Rosenblatt JE. Anaerobic bacteremia and cardiovascular infections. In: Finegold SM, George WL, editors. Anaerobic Infections in Humans. San Diego: Academic Press, Inc.; 1989. p. 289-310.
29. **Wilson WR**, Geraci JE. Infections caused by brucella, Francisella tularensis, Pasteurella, and Yersinia. In: Stein JH, editor. Internal Medicine. 3rd Edition. Boston: Little Brown and Company; 1990. p. 1496-505.
30. Steckelberg JM, Giuliani ER, **Wilson WR**. Infective endocarditis. In: Giuliani ER, Fuster V, Gersh BJ, McGoon MD, McGoon DC. Cardiology: Fundamentals and Practice. 2nd ed. Vol. 2. St. Louis: Mosby Year Book; 1991. p. 1734-73.
31. Asensio AT, Rodriguez AT, **Wilson WR**. Endocarditis infecciosa. Volume 1, Chpt. 19, pp. 208-209, 1992 in: Enfermedades Infecciosas Y Microbiologia Clinica. Evelio J. Perea, ed., Ediciones Doyma, S.A. Barcelona, Spain, 1992
32. Steckelberg JM, Murphy JG, **Wilson WR**. Management of complications of infective endocarditis. In: Kaye D. Infective Endocarditis. 2nd ed. New York: Raven Press; 1992. p. 435-53.
33. Osmon DR, Steckelberg JM, Wilhelm MP, Keating MR, Walker RC, Hanssen AD, **Wilson WR**. Medical management of total knee arthroplasty infection. Chpt 22, pp 377-392 in: Total Knee Arthroplasty. J.A. Rand, ed., Raven Press, Ltd., New York, 1992
34. Asensio AT, Rodriguez AT, **Wilson WR**. Septicemia y shock septico. Volume 1, chpt. 18, pp. 279-287, in: Enfermedades Infecciosas Y Microbiologia Clinica. Evelio J. Perea, Ed., Ediciones Doyma, S.A., Barcelona, Spain, 1992.
35. Osmon DR, Steckelberg JM, Wilhelm MP, Keating MR, Walker RC, Hanssen AD, **Wilson WR**. Medical management of total knee arthroplasty infection. In: Rand JA. Total Knee Arthroplasty. New York: Raven Press; 1993. p. 377-92.
36. **Wilson WR**, Thandroyen FT. Infective endocarditis. In: Willerson JT, Cohn JN, editors. Cardiovascular Medicine. New York: Churchill Livingstone; 1995. p. 240-56.
37. Henry NK, **Wilson WR**, Hendley JO. Infections caused by brucella, Francisella tularensis, Pasteurella, Yersinia species, and Bordetella pertussis (whooping cough). In: Stein JH, editor. Internal Medicine. St. Louis: Mosby; 1998. p. 1604-13.
38. Miro JM, **Wilson WR**. Infective endocarditis and other vascular infections in intravenous drug abusers. In: Mandell GL, Korzenowski OM, editors. Atlas of Infectious Diseases. Volume X: Cardiovascular Infections. Volume X. Philadelphia: Churchill Livingstone; 1998. p. 1.1.-1.20.
39. Rouse MS, **Wilson WR**. General methodologies for animal models. In: In: Zak O, Sande MA, editors. Handbook of Animal Models of Infection: Experimental Models in Antimicrobial Chemotherapy. San Diego: Academic Press; 1999. p. 9-12.
40. **Wilson WR**, Barasch E. Infective endocarditis. In: Willerson JT, Cohn JN, editors. Cardiovascular Medicine. Second Edition. New York: Churchill Livingstone; 2000. p. 401-19.

41. Berbari EF, **Wilson WR**. Brucella, Francisella, pasteurilla, Yersinia and HACEK. In: Wilson WR, Sande MA, editors. Current diagnosis & treatment in infectious diseases. New York: Lange Medical Books/McGraw-Hill; 2001. p. 630-43.
42. Badley AB, Steckelberg JM, **Wilson WR**. Cestodes. In: Wilson WR, Sande MA. Current diagnosis & treatment in infectious diseases. New York: Lange Medical Books/McGraw-Hill; 2001. p. 863-71.
43. **Wilson WR**, Steckelberg JM. Ectoparasitic infestations, arthropod stings, and bites. In: Wilson WR, Sande MA. Current Diagnosis & Treatment in Infectious Diseases. New York: Lange Medical Books/McGraw-Hill; 2001. p. 899-905.
44. **Wilson WR**. General principles of antimicrobial therapy. In: Wilson WR, Sande MA, editors. Current Diagnosis & Treatment in Infectious Diseases. New York: Lange Medical Books/McGraw-Hill; 2001. p. 28-32.
45. Steckelberg JM, **Wilson WR**. Infective endocarditis. In: Wilson WR, Sande MA. Current Diagnosis & Treatment in Infectious Diseases. New York: Lange Medical Books/McGraw-Hill; 2001. p. 155-76.
46. Steckelberg JM, **Wilson WR**. Nematodes. In: Wilson WR, Sande MA. Current Diagnosis & Treatment in Infectious Diseases. New York: Lange Medical Books/McGraw-Hill; 2001. p. 855-62.
47. Dockrell D, **Wilson WR**. Pseudomonas aeruginosa. In: Wilson WR, Sande MA, editors. Current diagnosis & treatment in infectious diseases. New York: Lange Medical Books/McGraw-Hill; 2001. p. 567-80.
48. Virk A, **Wilson WR**. Tracheobronchitis and lower respiratory tract infections. In: Wilson WR, Sande MA, editors. Current Diagnosis & Treatment in Infectious Diseases. New York: Lange Medical Books/McGraw-Hill; 2001. p. 118-54.
49. **Wilson WR**, Steckelberg JM. Trematodes. In: Wilson WR, Sande MA. Current Diagnosis & Treatment in Infectious Diseases. New York: Lange Medical Books/McGraw-Hill; 2001. p. 872-6.
50. **Wilson WR**, Henry NK. Urinary tract infections. In: Wilson WR, Sande MA, editors. Current Diagnosis & Treatment in Infectious Diseases. New York: Lange Medical Books/McGraw-Hill; 2001. p. 220-30.
51. Baddour LM, **Wilson WR**. Infections of prosthetic valves and other cardiovascular devices. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 6th Edition. Volume 1. Philadelphia: Elsevier Churchill Livingstone; 2005. p. 1022-44.
52. Pflueger A, **Wilson WR**. Infective endocarditis. In: Oliveira GHM, Nesbitt GC, Murphy JG, editors. Mayo Clinic medical manual. Boca Raton: Mayo Clinic Scientific Press, Taylor & Francis Group; 2006. p. 615-40.
53. Baddour LM, Taubert KA, Gewitz MH, **Wilson WR**. Infective endocarditis. In: The AHA guidelines and scientific statements handbook. 2009. p. 312-35.
54. Sohail MR, **Wilson WR**, Baddour LM. Infections of nonvalvular cardiovascular devices. In: Mandell GL; Bennett JE; Dolin R editor. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 7th Edition. Philadelphia: Churchill Livingstone/Elsevier; 2010. p. 1127-42.
55. Knoll BM, Baddour LM, **Wilson WR**. Prosthetic valve endocarditis. In: Mandell GL; Bennett JE; Dolin R editor. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 7th Edition. Philadelphia: Churchill Livingstone/Elsevier; 2010. p. 1113-26.

56. Baddour LM, Freeman WK, Suri RM, **Wilson WR**. Cardiovascular infections. In: Mann DL, Zipes DP, Libby P, Bonow RO. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 10th ed. Philadelphia: Elsevier/Saunders; 2014. p. 1524-50.
57. Sohail MR, **Wilson WR**, Baddour LM. Infections of nonvalvular cardiovascular devices. In: Bennett JE; Dolin R; Blaser MJ editor. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Eighth Edition. Volume 1. Philadelphia: Elsevier/Saunders; 2015. p. 1041-56.
58. Palraj R, Knoll BM, Baddour LM, **Wilson WR**. Prosthetic valve endocarditis. In: Bennett JE; Dolin R; Blaser MJ editor. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Eighth Edition. Volume 1. Philadelphia: Elsevier/Saunders; 2015. p. 1029-40.

Editorials

1. **Wilson WR**. Current therapeutic problems and management of respiratory tract infections--introduction. *Curr Ther Res Clin Exp*. 1994; 55(Suppl A):1.
2. Miro JM, **Wilson WR**. Infectious endocarditis - perspectives towards 2000. *Med Clin (Barc)* 1995 Jan 21; 104:55-58.
3. **Wilson WR**. New strategies in the therapy of infective endocarditis. (Spanish). *Rev Clin Esp*. 1995 Mar; 195:131-133.
4. Steckelberg JM, **Wilson WR**. Infections associated with implantable cardioverter defibrillators - still more questions - response. *Clin Infect Dis*. 1998 Aug; 27(2):270-271.
5. Baddour LM, Bettmann MA, Bolger AF, Epstein AE, Ferrieri P, Gerber MA, Gewitz MH, Jacobs AK, Levison ME, Newburger JW, Pallasch TJ, **Wilson WR**, Baltimore RS, Falace DA, Shulman ST, Tani LY, Taubert KA. Nonvalvular cardiovascular device-related infections. *Clin Infect Dis*. 2004 Apr 15; 38(8):1128-30.
6. Song JH, **Wilson W**. Introduction. *Int J Antimicrob Agents*. 2015 May; 45:IX.

Commentaries

1. DeSimone DC, Tleyjeh IM, Correa de Sa DD, Anavekar NS, Lahr BD, Sohail MR, Steckelberg JM, **Wilson WR**, Baddour LM. Response to letter regarding article, "Incidence of infective endocarditis due to viridans group streptococci before and after publication of the 2007 American Heart Association's endocarditis prevention guidelines". *Circulation*. 2013 Mar 26; 127(12):e521. PMID:23646371 DOI:
2. Osmon DR, Barbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM, Rao N, Hanssen A, **Wilson WR**. Reply to Eisen and Denholm, Dauchy et al, Fierer, and Nguyen and Jones. *Clin Infect Dis*. 2013 Jul; 57(1):162-4. Epub 2013 Mar 28. PMID:23537909 DOI:10.1093/cid/cit189

Audio/Video/CD-ROM/etc.

1. Nasser FN, Giuliani ER, **Wilson WR**. Infective endocarditis and cardiac complications demonstrated by 2-dimensional echocardiography. Mayo Clinic, 1980.

Letters

1. **Wilson WR**, Washington JA 2nd. Infective endocarditis--a changing spectrum. *Mayo Clin Proc.* 1977 Apr; 52(4):254-5. PMID:846225 DOI:
2. Gambertoglio JG, **Wilson WR**, Van Scoy RE. Dosage of vancomycin. *Mayo Clin Proc.* 1978 Mar; 53(3):197-8. PMID:628229 DOI:
3. Freidig EE, Smith TF, **Wilson WR**. Failure to recover chlamydia trachomatis from open-lung biopsy tissue of adult immunosuppressed patients. *Chest.* 1984 Oct; 86:649. PMID:6478914 DOI:
4. **Wilson WR**. Antimicrobial agents. *Mayo Clin Proc.* 1988 Feb; 63:211.
5. Khandheria BK, Steckelberg JM, Anhalt JP, Ballard DJ, Seward JB, Click RL, **Wilson WR**. Transesophageal echocardiography and bacterial endocarditis. *Circulation.* 1993 Apr; 87(4):1426-7. PMID:8462171 DOI:
6. Brandt CM, Rouse M, Laue N, Stratton CW, **Wilson WR**, Steckelberg JM. Importance of using relapse studies or tests for detection of antibiotic resistance before considering that a treatment for multidrug-resistant enterococcal experimental endocarditis is effective - reply. *J Infect Dis.* 1997 Jan; 175(1):233.
7. **Wilson WR**, Steckelberg JM, Keating MR. Infectious Diseases Society of America position statement on the role of hospital pharmacists. *Clin Infect Dis.* 1998 Jul; 27(1):228. PMID:9675491 DOI:
8. Baddour LM, Steckelberg JM, **Wilson WR**. Comment on: The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials. *J Antimicrob Chemother.* 2006 Jun; 57(6):1255; author reply 1255-6. Epub 2006 Mar 20. PMID:16549509 DOI:10.1093/jac/dkl100
9. Sohail MR, **Wilson WR**, Baddour LM, Steckelberg JM, Martin KR, Harmsen WS. Treatment of Staphylococcus aureus prosthetic valve endocarditis - The reply. *Am J Med.* 2007 Mar; 120(3):E11.
10. Chintakuntlawar A, Kidd M, Al-Kali A, **Wilson W**, Thompson CA. Toxoplasmosis in patients with hematologic malignancies. *Leuk Lymphoma.* 2015; 56(2):536-8. PMID:24882256 DOI:
11. DeSimone DC, **Wilson WR**, Baddour LM. Trends in Infective Endocarditis Incidence, Microbiology, and Valve Replacement in the United States From 2000 to 2011: The Devil Is in the Details. *J Am Coll Cardiol* 2015 Sep 8; 66 (10):1201-2 PMID:26338002 DOI:10.1016/j.jacc.2015.05.079

Abstracts

1. **Wilson WR**, Ritts RE Jr, Hermans PE. Late-onset combined immune deficiency. (Abstract 141). 14th Interscience Conference on Antimicrobial Agents and Chemotherapy, Sep 11-13, 1974, San Francisco, California.. 1974;
2. **Wilson WR**, Jaumin PM, Giuliani ER, Danielson GK, Washington JA II. Prosthetic valve endocarditis. (Abstract 80). 14th Interscience Conference on Antimicrobial Agents and Chemotherapy, Sep 11-13, 1974, San Francisco, California.. 1974;
3. **Wilson WR**, Jaumin PM, Danielson GK, Washington JA II, Giuliani ER, Geraci JE. Cardiac valve replacement in patients with congestive heart failure (CHF) caused by infective endocarditis (IE). (Abstract 195). 15th Interscience Conference on Antimicrobial Agents and Chemotherapy, Sep 24-26, 1975, Washington, D.C.. 1975;
4. Molenaar DM, Palumbo PJ, **Wilson WR**, Ritts RE Jr. Impaired leukocyte chemotaxis in non-diabetic relatives of patients with juvenile-onset diabetes. *Diabetes.* 1975; 24(Suppl 2):401.

5. Molenaar DM, Palumbo PJ, **Wilson WR**, Ritts RE Jr. Leukocyte chemotaxis in diabetic patients and their first-degree non-diabetic relatives. *Clin Res.* 1975 Apr; 23:326A.
6. Geraci JE, **Wilson WR**, Wilkowske CJ. Haemophilus endocarditis (HE): report of 13 cases. (Abstract 75). 16th Interscience Conference on Antimicrobial Agents and Chemotherapy, Oct 27-29, 1976, Chicago, Illinois.. 1976;
7. **Wilson WR**, Geraci JE, Wilkowske CJ. Short-term intramuscular therapy (IM) with procaine penicillin plus streptomycin (pp&s) for infective endocarditis (IE) due to streptococci of the viridans group (sv). (Abstract 220). 16th Interscience Conference on Antimicrobial Agents and Chemotherapy, Oct 27-29, 1976, Chicago, Illinois.. 1976;
8. Krawisz JE, Palumbo PJ, Taswell HF, **Wilson WR**. HL-A8 and leukocyte chemotaxis in juvenile-onset diabetics and their first-degree relatives. *Diabetes.* 1976 Jun; 25(Suppl 1):371.
9. **Wilson WR**, Geraci JE, Giuliani ER, Danielson GK, Washington JA II, Spittell JA Jr. Anticoagulant therapy in patients with prosthetic valve endocarditis. *Circulation.* 1976 Oct; 54(Suppl II):II-22.
10. Thompson RL, **Wilson WR**, Van Scoy RE, Ritts RE Jr, Tomasi TB Jr, Hermans PE. Immunologic responsiveness in patients with subacute bacterial endocarditis (SBE). *American Society for Microbiology (Icalc)*.. 1978.
11. **Wilson WR**, Geraci JE, Thompson RJ, Wilkowske CJ, Giuliani ER. Treatment of penicillin-sensitive streptococcal infective endocarditis (pssie) with short-term intramuscular (IM) procaine penicillin and streptomycin (pp&s). (Abstract 276). Eighteenth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D C, 1978. 1978;
12. Geraci JE, Greipp PR, Wilkowske CJ, **Wilson WR**, Washington JA II. *Cardiobacterium hominis* endocarditis: four cases with clinical and laboratory observations. *Microbiol Abstracts.* 1978 Oct; 13:105.
13. **Wilson WR**, Giuliani ER. Infective endocarditis. I. Rochester, Minn, *Clinical Reviews.* 1978 Oct-Nov; 102-5.
14. Giuliani ER, **Wilson WR**. Infective endocarditis. II. Rochester, Minn, *Clinical Reviews.* 1978 Oct-Nov; 38-9.
15. **Wilson WR**, Thompson RL. New cephalosporins: what do they do and who needs them? Rochester, Minnesota, *Clinical Reviews.* 1979 Oct-Nov; 94-5.
16. **Wilson WR**, Geraci JE, Giuliani ER, Thompson RL, Wilkowske CJ. Short-term intramuscular therapy with procaine penicillin plus streptomycin for infective endocarditis due to penicillin-sensitive streptococci. (Abstract 132). *Circulation.* 1979 Oct; 60(PART II):II-36.
17. **Wilson WR**, Geraci JE, Wright AJ, Giuliani ER, Wilkowske CJ. Treatment of enterococcal endocarditis. (Abstract 1152). *Circulation.* 1980 Oct; 62(PART II):III-300.
18. **Wilson WR**, Gephart JF, Thompson RL, Washington JA II, Geraci JE. Infective endocarditis (IE) caused by nutritionally variant viridans streptococci (NVS). (Abstract 785). Program and Abstracts of the 21st Interscience Conference on Antimicrobial Agents and Chemotherapy, Conrad Hilton Hotel, Chicago, Illinois, Nov 4-6, 1981. Washington, D. C.,. 1981;

19. Auckenthaler R, **Wilson WR**, Wright AJ, Washington JA II, Geraci JE. Lack of in vivo and in vitro bactericidal activity of N-formimidoyl thienamycin-MK0787 (MK) against enterococci from patients with infective endocarditis (IE). (Abstract 595). Program and Abstracts of The 21st Interscience Conference on Antimicrobial Agents and Chemotherapy Conrad Hilton Hotel, Chicago, Illinois, Nov 4-6, 1981.. 1981;
20. **Wilson WR**, Keys TF, Mueller SM, Anhalt JP. Moxalactam (Mx) therapy of septicemia. (Abstract 316). Program and Abstracts of the 21st Interscience Conference on Antimicrobial Agents and Chemotherapy, Conrad Hilton Hotel, Chicago, Illinois, Nov 4-6, 1981. Washington, D. C.. 1981;
21. Henry NK, McLimans CA, Wright AJ, **Wilson WR**, Thompson RL, Washington JA II. Clinical evaluation of isolator blood culture system. (Abstract 402). Program and Abstracts of the Twenty-Second Interscience Conference on Antimicrobial Agents and Chemotherapy, October 4-6, 1982, Miami Beach, Florida. Sponsored by American Society for Microbiology, 1982. 1982; 136.
22. Henry NK, McLimans CA, Washington JA II, Wright AJ, Thompson RL, **Wilson WR**. Evaluation of the isolator (Dupont) system for detecting septicemia. (Abstract C 126). Abstracts of the Annual Meeting of the American Society for Microbiology, March 7-12, 1982. 1982; 292.
23. Roberts RB, **Wilson WR**, Bouvet A, Acar J. Nutritionally variant streptococcal (nvs) endocarditis. (Abstract 365). Program and Abstracts of the Twenty-Second Interscience Conference on Antimicrobial Agents and Chemotherapy, October 4-6, 1982, Miami Beach, Florida. Sponsored by American Society for Microbiology, 1982. 1982; 130.
24. Zak O, Sande MA, **Wilson WR**. Penicillin (P) or P plus streptomycin (s) therapy (Rx) for viridans streptococcal (vir-s) experimental endocarditis (EE). (Abstract 839). Program and Abstracts of the Twenty-Second Interscience Conference on Antimicrobial Agents and Chemotherapy, October 4-6, 1982, Miami Beach, Florida. Sponsored by American Society for Microbiology, 1982. 1982; 215.
25. Meyer BJ, Henry NK, **Wilson WR**, Roberts RB, Geraci JE. Treatment of nutritionally variant viridans streptococcal (nvs) endocarditis (e) in the experimental rabbit model. (Abstract 866). Program and Abstracts of the Twenty-Third Interscience Conference on Antimicrobial Agents and Chemotherapy, Las Vegas, Nevada, October 24-26, 1983. Sponsored by the American Society for Microbiology. 1983:243.
26. Fitzgerald RH, Henry NK, **Wilson WR**, Ilstrup DM, Kelly PJ. Treatment of musculoskeletal sepsis with moxalactam or convention antimicrobial therapy: a randomized, prospective study. 13th International Congress of Chemotherapy. Vienna, Austria, 1983 Aug.
27. Enzler MJ, Rouse MS, Backes RJ, Henry NK, Geraci JE, **Wilson WR**. Treatment (Rx) of highly streptomycin-resistant viridans streptococcal experimental endocarditis. (Abstract 339). Program and Abstracts of the Twenty-Fourth Interscience Conference on Antimicrobial Agents and Chemotherapy. 1984; 151.
28. Libertin CR, Cockerill FR III, **Wilson WR**, Smith TF. Pneumocystis carinii pneumonia American Journal of Clinical Pathology. 1984 Mar; 81:399-400.
29. Freidig EE, McClure SP, **Wilson WR**, Banks PM, Washington JA II. Clinical-histologic-microbiologic analysis of 487 lymph node (LN) biopsies. (Abstract 186). Program and Abstracts of the Twenty-Fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D C, October 8-10, 1984. Sponsored by the American Society for Microbiology. 1984 Oct 8-10; 122.

30. Fernandez-Guerrero M, Rouse MS, Henry NK, **Wilson WR**. In vitro and in vivo activity of ciprofloxacin against enterococci. (Abstract 275). Program and Abstracts of the Twenty-Fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D C, October 8-10, 1984. Sponsored by the American Society for Microbiology. 1984 Oct 8-10; 139.
31. Backes RJ, Henry NK, **Wilson WR**, Geraci JE. Penicillin or penicillin plus streptomycin therapy for group B streptococcal experimental endocarditis. Clin Res. 1984 Dec; 32:847A.
32. Walker RC, Rouse MS, Whitesell AL, **Wilson WR**, Henry NK. Comparison of ciprofloxacin and nafcillin treatment of *S. aureus* experimental osteomyelitis. (Abstract 210). Program and Abstracts of the Twenty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, Minneapolis, Minn, Sept 29-Oct 2, 1985. (Sponsored by the American Society for Microbiology). 1985; 128.
33. Enzler MJ, Rouse MS, Henry NK, **Wilson WR**. Influence of inoculum size on treatment of experimental *S. bovis* endocarditis. (Abstract 470). Program and Abstracts of the Twenty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy. 1985; 177.
34. Lam JB, Tajik AJ, **Wilson WR**, Seward JB. Infective endocarditis: six-year experience with 2-D echocardiography. J Am Coll Cardiol. 1985 Feb; 5(PART 2):530.
35. Fernandez-Guerrero ML, Henry NK, **Wilson WR**. In vitro and in vivo activity of ciprofloxacin against methicillin-sensitive staphylococcus aureus. (Abstract A-17). Abstracts of the Annual Meeting of the American Society for Microbiology. 1985 Mar 3-7.
36. Henry NK, Schultz HJ, Grubbs NC, Muller SM, Ilstrup DM, **Wilson WR**. Comparison of ciprofloxacin vs trimethoprim/sulfamethoxazole in the treatment of uncomplicated urinary tract infection in women. (Abstract 403). Program and Abstracts of the Twenty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans, Louisiana, Sep 28-Oct 1, 1986. (Sponsored by the American Society for Microbiology). 1986; 171.
37. McConnell ME, Rouse MS, Henry NK, **Wilson WR**. In vitro activity of CGP 31608: a new penem. (Abstract 631). Program and Abstracts of the Twenty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans, Louisiana, Sept 28-Oct 1, 1986. (Sponsored by the American Society for Microbiology). 1986; 212.
38. Enzler MJ, Rouse MS, Henry NK, Geraci JE, **Wilson WR**. In vitro and in vivo activity of teicoplanin against viridans streptococcal experimental endocarditis. (Abstract 281). Program and Abstracts of the Twenty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy. 1986; 146.
39. Rouse MS, Wilcox RW, Enzler MJ, Henry NK, Geraci JE, **Wilson WR**. In vitro and in vivo activity of teicoplanin or ciprofloxacin against *Staphylococcus epidermidis*. (Abstract 289). Program and Abstracts of the Twenty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy. 1986; 148.
40. Rouse MS, Sarria-Cepeda C, McConnell ME, **Wilson WR**, Henry NK. Influence of pentoxifylline on the treatment of *Staphylococcus aureus* experimental osteomyelitis. (Abstract 545). Program and Abstracts of the Twenty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans, Louisiana, Sept 28-Oct 1, 1986. (Sponsored by the American Society for Microbiology). 1986; 196.
41. Telenti A, Guerra L, Roberts GD, **Wilson WR**. Usefulness of the lysis-centrifugation blood culture system for the clinical management of patients having fungemia. (Abstract 129). Program and Abstracts of the Twenty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans, Louisiana, Sept 28-Oct 1, 1986. (Sponsored by the American Society for Microbiology). 1986; 119.

42. Gerecht WB, Henry NK, Muller SM, **Wilson WR**. Imipenem/cilastin vs conventional therapy: a prospective controlled randomized study in non-neutropenic bacteremic patients. (Abstract 249). Program and Abstracts of the Twenty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans, Louisiana, Sept 28-Oct 1, 1986. (Sponsored by the American Society for Microbiology). 1986 Sep 28-Oct 1; 141.
43. **Wilson WR**. New antibiotics. Rochester, Minnesota Clinical Reviews. 1986 Oct/Nov; 122-3.
44. **Wilson WR**. The quinolone antibiotics: a new class of antimicrobial agents. Rochester, Minnesota Clinical Reviews. 1987 Oct/Nov; 132-4.
45. Rouse MS, McConnell ME, Keating MR, Steckelberg JM, **Wilson WR**, Henry NK. Treatment of methicillin-resistant *S. aureus* experimental osteomyelitis with LY 146032 or vancomycin in combination with rifampin Program and Abstracts of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, NY, American Society for Microbiology. 1987 Oct 4-7.
46. Enzler MJ, McConnell M, LeRoy AJ, Williams HJ Jr, **Wilson WR**, Rouse M. Nutritionally variant viridans streptococcal native valve endocarditis. 28th Interscience Conference on Antimicrobial Agents and Chemotherapy Program and Abstracts. 1988 Oct:142. Abstract no. 187.
47. Hellinger WC, Rouse MS, Stock JA, Henry NK, **Wilson WR**. Continuous intravenous (CI) ampicillin (AMP) treatment of aminoglycoside resistant enterococcal experimental endocarditis. (Abstract 1512). 28th Interscience Conference on Antimicrobial Agents and Chemotherapy Program and Abstracts: Los Angeles, California. 1988 Oct 23-26:174.
48. Rouse MS, Tallan BM, Steckelberg JM, **Wilson WR**, Henry NK. A novel model of *S. epidermidis* experimental foreign body osteomyelitis: treatment with ciprofloxacin (cp) or vancomycin (vn). (Abstract 1319). Program and Abstracts of the Twenty-Ninth Interscience Conference on Antimicrobial Agents and Chemotherapy. 1989; 325.
49. Ormand JE, Talley NJ, Shorter RG, Conley CR, **Wilson WR**, Phillips SF. *Campylobacter pylori* prevalence in specific forms of gastritis: further evidence supporting a pathogenic role for *C. pylori* in chronic antral gastritis. *Gastroenterology*. 1989; 96:A378.
50. Tallan BM, Rouse MS, Henry NK, Steckelberg JM, Dorsher CB, **Wilson WR**. Comparative beta-lactum activity in staphylococcus aureus experimental endocarditis. (Abstract 975). Program and Abstracts of the Twenty-Ninth Interscience Conference on Antimicrobial Agents and Chemotherapy. 1989:267.
51. Tallan BM, Rouse MS, Rabadan PM, Henry NK, Steckelberg JM, **Wilson WR**. In vivo activity of SKF 104662 against enterococci. (Abstract 969). Program and Abstracts of the Twenty-Ninth Interscience Conference on Antimicrobial Agents and Chemotherapy. 1989; 263.
52. Steckelberg JM, Murphy JG, Ballard DJ, Taliencio CP, Bailey KR, Geraci JE, **Wilson WR**. Incidence rates of macroembolic events in infective endocarditis (ie). (Abstract/poster presentation 534). Program and Abstracts of the Twenty-Ninth Interscience Conference on Antimicrobial Agents and Chemotherapy. 1989; 191.
53. Steckelberg JM, Ilstrup DM, Rouse MS, Geraci JE, Melton LJ, **Wilson WR**. Increase in incidence of infective endocarditis (ie) with age: a population-based study. (Abstract 533). Program and Abstracts of the Twenty-Ninth Interscience Conference on Antimicrobial Agents and Chemotherapy. 1989; 190.
54. Ormand JE, Talley NJ, Carpenter HA, Fich A, Shorter RG, Conley CR, **Wilson WR**, Rouse MS, DiMagno EP, Phillips SF, Zinsmeister AR. Prevalence of *Campylobacter pylori* in asymptomatic southern Minnesota volunteers. *Am J Gastroenterol*. 1989; 84:1167.

55. Ormand JE, Talley NJ, Shorter RG, Conley CR, Carpenter HA, **Wilson WR**, Phillips SF. Campylobacter pylori (cp) prevalence in Crohn's gastritis and Menetrier's disease. (Abstract no. 109). Am J Gastroenterol. 1989 Sep; 84(9):1166.
56. Ormand JE, Talley NJ, Carpenter HA, Shorter RG, Conley CR, Batts KP, **Wilson WR**, Rouse MS, DiMagno EP, Zinsmeister AR. Effect of age on the diagnosis of Campylobacter pylori (cp) using the c14-urea breath test. (Abstract 110). Am J Gastroenterol. 1989 Sep; 84(9):1166.
57. Murphy JG, Steckelberg JM, Taliercio P, **Wilson WR**, Ballard DJ, Giuliani ER, Tajik AJ. Systemic embolization in hospital treated infective endocarditis at a tertiary medical center: importance of antibiotic therapy. (Abstract 2657). Circulation. 1989 Oct; 80(Suppl):II-669.
58. Steckelberg JM, Khandheria BK, Anhalt JP, Click RL, Seward JB, **Wilson WR**. Risk of bacteremia associated with transesophageal echocardiography (TEE). Circulation. 1990; 82(Suppl III):III-244.
59. Henry NK, Tallan BM, Toorkey CM, Steckelberg JM, Rhodes KH, **Wilson WR**. Treatment of B-lactamase positive (BLP) haemophilus influenzae type B (HIB) experimental pneumonia in mice. (Abstract A-133). Abstracts of the 90th General Meeting of the American Society of Microbiology. 1990 1990; 90:23.
60. Tallan BM, Rouse MS, Henry NK, Steckelberg JM, **Wilson WR**. Ceftriaxone treatment of S. aureus experimental endocarditis. (Abstract 364). Interscience Conference on Antimicrobial Agents and Chemotherapy. 1991; 159.
61. Ang B, Telenti A, Steckelberg JM, **Wilson WR**. Clinical characteristics of candidemia from urinary tract source. (Abstract no. 1260). Interscience Conference on Antimicrobial Agents and Chemotherapy. 1991; 309.
62. Tallan BM, Rouse MS, Kernodle DS, Steckelberg JM, Henry NK, **Wilson WR**. Effect of quantity and location of S. aureus beta-lactamase on outcome of cephalosporin treatment of experimental endocarditis. (Abstract 363). Interscience Conference on Antimicrobial Agents and Chemotherapy. 1991; 159.
63. Rouse MS, Tallan BM, Ang BSP, Hughes CE, Henry NK, Steckelberg JM, **Wilson WR**. Fluconazole treatment of experimental candidiasis. (Abstract no. 583) Interscience Conference on Antimicrobial Agents and Chemotherapy. 1991; 196.
64. Tallan BM, Ang BSP, Rouse MS, Henry NK, **Wilson WR**, Steckelberg JM. Fluoroquinolone treatment of streptococcus pneumoniae experimental pneumonia in mice. (Abstract no. 1200). Interscience Conference on Antimicrobial Agents and Chemotherapy. 1991; 299.
65. Osmon DR, Steckelberg JM, Ang BSP, Hanssen AD, **Wilson WR**. The significance of routine surveillance cultures in predicting primary prosthetic hip infection. (Abstract 1284). Interscience Conference on Antimicrobial Agents and Chemotherapy 313, 1991.
66. Murphy JG, Gersh BJ, Steckelberg JM, Kopecky SL, Mair DD, Kirklin JW, Danielson GK, **Wilson WR**. Risk of late endocarditis following congenital heart repair: 30-year follow-up in 610 patients. J Am Coll Cardiol. 1991 Feb; 17(Suppl A):135A.
67. Tallan BM, Henry NK, Rouse MS, **Wilson WR**, Steckelberg JM. Pulmonary clearance of haemophilus influenzae type B in mice. Chest. 1991 Aug; 100(Suppl):146S.
68. Rouse MS, Tallan BM, Henry NK, Steckelberg JM, **Wilson WR**. Treatment of Xanthomonas maltophilia experiment pneumonia in mice. Chest. 1991 Aug; 100(Suppl):147S.

69. Rouse MS, Hnery NK, **Wilson WR**, Steckelberg JM. Cefpirome Treatment of Methicillin-Sensitive Staphylococcus aureus Experimental Endocarditis. 11th Interdisciplinary Meeting on Anti-Infectious Chemotherapy. Paris, France. 1991 Dec:P15. Abstract no. 212/P150.
70. Ang BSP, Osmon D, Rouse MS, Tallan BM, **Wilson WR**, Steckelberg JM. Treatment of C.albicans Experimental Foreign Body Osteomyelitis with Fluconazole Impregnated Bone Cement (Abstract PS 4.19). Handbook and Abstracts of the 3rd Western Pacific Congress on Chemotherapy and Infectious Diseases Nusa Dua Bali, Indonesia. 1992 Dec
71. Brandt CM, Rouse MS, Tallan BM, Laue NW, Stratton CW, **Wilson WR**, Steckelberg JM. Effective treatment of multidrug resistant enterococcal experimental endocarditis with combinations of cell-wall active agents. Program Abstr - Intersci Conf Antimicrob Agents Chemother. 1994; 34:150.
72. Song JH, Laue NW, Rouse MS, **Wilson WR**, Steckelberg JM. In vitro interaction between cefotaxime and erythromycin against respiratory tract pathogens. Program Abstr - Intersci Conf Antimicrob Agents Chemother. 1994; 34:222.
73. Rouse MS, Brandt CM, Laue NW, **Wilson WR**, Steckelberg JM. Effect of lisofylline on ampicillin treatment of pneumococcal experimental pneumonia. Program Abstr - Intersci Conf Antimicrob Agents Chemother. 1995; 35:16.
74. **Wilson WR**. Enterococcal endocarditis: from a walk in the park to Jurassic Park. Circulation. 1995; 92(8 Suppl):ID.
75. Laue NW, Rouse MS, Brandt CM, Osmon DR, **Wilson WR**, Steckelberg JM. In vitro activity of erythromycin or clarithromycin in combination with cefuroxime against respiratory pathogens. Abstracts of the General Meeting of the American Society for Microbiology. 1995; 95:57.
76. Rouse MS, Brandt CM, Laue NW, Miro JM, **Wilson WR**, Steckelberg JM. Macrolides compared with amoxicillin for prophylaxis of viridans streptococcal experimental endocarditis. Abstracts of the General Meeting of the American Society for Microbiology. 1995; 95:163.
77. Rouse MS, Laue NW, **Wilson WR**, Steckelberg JM. RU 59863 treatment of pseudomonas aeruginosa experimental pneumonia in mice. Program Abstr - Intersci Conf Antimicrob Agents Chemother. 1995; 35:123.
78. Rouse MS, Piper KE, Patel P, **Wilson WR**, Steckelberg JM. Extended spectrum cephalosporin treatment of penicillin-resistant pneumococcal experimental pneumonia in immunocompetent mice. Program Abstr - Intersci Conf Antimicrob Agents Chemother. 1996; 36:29.
79. Rouse MS, Piper KE, Patel R, Cockerill FR, **Wilson WR**, Steckelberg JM. In vitro activity of LY 333328 against vancomycin resistant (vanA, vanB, vanC-1, vanC-2) enterococci. Program Abstr - Intersci Conf Antimicrob Agents Chemother. 1996; 36:135.
80. Rouse MS, Piper KE, Patel R, **Wilson WR**, Steckelberg JM. In vitro and in vivo activity of BAY12-8039 or trovafloxacin against penicillin-resistant Streptococcus pneumoniae experimental pneumonia in immunocompetent mice. Program Abstr - Intersci Conf Antimicrob Agents Chemother. 1996; 36:29.
81. Rouse MS, Patel R, **Wilson WR**, Steckelberg JM. Levofloxacin plus cefotaxime treatment of methicillin-sensitive Staphylococcus aureus experimental osteomyelitis. Abstracts of the General Meeting of the American Society for Microbiology. 1996; 96:134.

82. Piper KE, Rouse MS, Patel R, **Wilson WR**, Steckelberg JM. RU 004 treatment of beta-lactamase positive H. Influenzae type B experimental pneumonia in immunocompetent mice. Program Abstr - Intersci Conf Antimicrob Agents Chemother. 1996; 36:31.
83. Piper KE, Rouse MS, Patel R, **Wilson WR**, Steckelberg JM. Azithromycin treatment of clarithromycin intermediately susceptible H. influenzae type B experimental pneumonia (Abstract 38). Abstracts of the General Meeting of the American Society for Microbiology. 1997; 97:7.
84. Huddleston PM, Rouse MS, Piper KE, **Wilson WR**, Steckelberg JM. Ciprofloxacin treatment of implant stabilized experimental infected fractures in a rat model. (Abstract 31) Abstracts of the General Meeting of the American Society for Microbiology. 1997; 97:6.
85. Rouse MS, Piper KE, Patel R, **Wilson WR**, Steckelberg JM. In vitro and in vivo activity of ciprofloxacin, levofloxacin, sparfloxacin or BAY12-8039 against penicillin-resistant Streptococcus pneumoniae. Program Abstr - Intersci Conf Antimicrob Agents Chemother. 1997; 37:26.
86. Rouse MS, Piper KE, Patel R, **Wilson WR**, Steckelberg JM. In vitro and in vivo activity of trovafloxacin against methicillin-susceptible Staphylococcus aureus experimental endocarditis. Program Abstr - Intersci Conf Antimicrob Agents Chemother. 1997; 37:31.
87. Rouse MS, Piper KE, Cockerill FR, **Wilson WR**, Steckelberg JM. Treatment of group a streptococcal experimental soft tissue infection (Abstract 33). Abstracts of the General Meeting of the American Society for Microbiology. 1997; 97:6.
88. Piper KE, Rouse MS, Patel R, **Wilson WR**, Steckelberg JM. Trovafloxacin treatment of H. Influenzae type B experimental pneumonia in immunocompetent mice (Abstract 34). Abstracts of the General Meeting of the American Society for Microbiology. 1997; 97:6.
89. Piper KE, Rouse MS, Patel R, **Wilson WR**, Steckelberg JM. Trovafloxacin treatment of viridans streptococcal experimental endocarditis. Program Abstr - Intersci Conf Antimicrob Agents Chemother. 1997; 37:30.
90. Piper KE, Rouse MS, Patel R, **Wilson WR**, Steckelberg JM. HMR 3647 treatment of beta-lactamase positive Haemophilus influenzae type B experimental pneumonia in immunocompetent mice. Program Abstr - Intersci Conf Antimicrob Agents Chemother. 1998; 38:56.
91. Piper KE, Rouse MS, Patel R, **Wilson WR**, Steckelberg JM. In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci. Program Abstr - Intersci Conf Antimicrob Agents Chemother. 1998; 38:205.
92. Rouse MS, Piper KE, Patel R, **Wilson WR**, Steckelberg JM. In vitro and in vivo activity of ciprofloxacin, levofloxacin, or vancomycin against macrolide-resistant, penicillin-resistant Streptococcus pneumoniae. Program Abstr - Intersci Conf Antimicrob Agents Chemother. 1998; 38:56.
93. Brown ML, Rouse MS, Piper KE, **Wilson WR**, Patel R, Steckelberg JM. In vitro emergence of resistance of S. aureus to quinolone antimicrobials. Abstracts of the General Meeting of the American Society for Microbiology. 1998; 98:43.
94. Florez MV, Rouse MS, Piper KE, Patel R, Cockerill FR, **Wilson WR**, Steckelberg JM. Penicillin and clindamycin and intravenous immune globulin against group A streptococci. Abstracts of the General Meeting of the American Society for Microbiology. 1998; 98:51.

95. Rouse MS, Piper KE, Patel R, **Wilson WR**, Steckelberg JM. In vitro and in vivo emergence of resistance among *S. aureus* to ciprofloxacin, levofloxacin, moxifloxacin or trovafloxacin (Abstract P-806) 9th European Congress of Clinical Microbiology and Infectious Diseases, Berlin. 1999;
96. Wilson JW, Vetter EA, Torgerson CA, Harmsen WS, Ilstrup DM, **Wilson WR**, Cockerill FR. Optimal volume of blood, frequency of collection and incubation period for diagnosing blood stream infections. Abstracts of the General Meeting of the American Society for Microbiology. 1999; 99:208.
97. Prpa B, Rouse M, Piper KE, Hanssen AD, Patel R, Steckelberg JM, **Wilson WR**. The effect of ciprofloxacin or trovafloxacin on experimental fracture healing. Program Abstr - Intersci Conf Antimicrob Agents Chemother. 1999; 39:40.
98. Piper KE, Rouse MS, **Wilson WR**, Steckelberg JM, Patel R. Treatment of methicillin-sensitive *Staphylococcus aureus* experimental osteomyelitis with linezolid or cefazolin. Program Abstr - Intersci Conf Antimicrob Agents Chemother. 1999; 39:41.
99. Pachirat O, Sarano ME, Sinak LJ, Bailey KR, Steckelberg JM, **Wilson WR**. Transesophageal echocardiography should be the preferred approach to obtain Duke criteria for diagnosis of infective endocarditis. *Circulation*. 1999 Nov 2; 100(18 Suppl):I.654.
100. Piper KE, Rouse MS, **Wilson WR**, Steckelberg JM, Patel R. In vitro activity of GAR-936 against vancomycin resistant enterococci, methicillin-resistant *Staphylococcus aureus*, and penicillin-resistant pneumococci. Program Abstr - Intersci Conf Antimicrob Agents Chemother. 2000; 40:169.
101. Tleyjeh IM, Haidar WN, Moustafa SE, Anavekar NS, Mirzoyev Z, Anavekar NS, Ghomrawi HM, **Wilson WR**, Steckelberg JM, Baddour LM. Several baseline variables are independent predictors of 6-month mortality in elderly patients with left-sided infective endocarditis (Abstract 1686). *Circulation*. 2005 Oct; 112(17 Suppl):II-338-9.
102. Anavekar NS, Anavekar NS, Tleyjeh I, Mirzoyev Z, Haddad C, Kandakher M, Tajik J, **Wilson W**, Steckelberg JM, Chandrasekaran K, Baddour LM. Baseline characteristics associated with embolism in infective endocarditis (Abstract 984-26). *J Am Coll Cardiol*. 2006 Feb; 47(4 Suppl A):281A.
103. Anavekar NS, Tleyjeh I, Anavekar NS, Mirzoyev Z, Haddad C, Khandaker M, Tajik J, **Wilson W**, Steckelberg J, Chandrasekaran K, Baddour LM. Impact of chronic, daily antiplatelet therapy on embolic events in infective endocarditis (Abstract 984-19). *J Am Coll Cardiol*. 2006 Feb; 47(4 Suppl A):279A-280A.
104. Uslan DZ, Dowsley TF, Sohail MR, Hayes DL, Friedman PA, **Wilson WR**, Steckelberg JM, Baddour LM. *Staphylococcus aureus* bacteremia in patients with cardiac devices: risk factors for device infection. *Clinical Research in Cardiology*. 2007 Jun; 96(6):449.
105. Correa de Sa D, Tleyjeh I, Schultz J, Thomas J, Bachuwar A, Pazdernik M, Anavekar N, Steckelberg J, **Wilson W**, Baddour L. Recent trends in the epidemiology of infective endocarditis: a population-based study in olmsted county, minnesota. *Int J Antimicrob Agents*. 2009 Apr; 33:S2.
106. Coelho-Prabhu N, Oxentenko A, Osmon D, Baron T, Hanssen A, **Wilson W**, Steckelberg J, Baddour L, Harmsen W, Mandrekar J, Berbari E. Are gastrointestinal endoscopic procedures associated with an increased risk of prosthetic joint infection (PJI)? *Am J Gastroenterol*. 2009 Oct; 104(Suppl 3):1387.
107. Madhavan M, Sohail MR, Friedman PA, Hayes DL, Steckelberg JM, **Wilson WR**, Baddour LM. Cardiovascular implantable electronic device infection in patients with non-staphylococcus aureus gram-positive coccal bacteremia. *Circulation*. 2009 Nov 3; 120(Suppl 2):S648-9.

108. Boland JM, Chung H, Robberts FJL, **Wilson WR**, Steckelberg JM, Greason KL, Baddour LM, Miller DV. Fungal prosthetic valve endocarditis: Mayo Clinic experience including a clinicopathologic analysis. *Mod Pathol*. 2010 Feb; 23(Suppl 1):1481.
109. Boland JM, Chung H, Robberts FJL, **Wilson WR**, Steckelberg JM, Greason KL, Baddour LM, Miller DV. Fungal prosthetic valve endocarditis: Mayo Clinic experience including a clinicopathologic analysis. *Lab Invest*. 2010 Feb; 90(Suppl 1):1481.
110. Tsaras G, Osmon DR, Hanssen AD, Baddour LM, Greene DG, Harmsen WS, Mandrekar JN, Steckelberg JM, **Wilson WR**, Berbari EF. Distant infection and the risk of Prosthetic Joint Infection (PJI): A case control study. *Int J Infect Dis*. 2010 Mar; 14(Suppl 1):E59.
111. DeSimone DC, Tleyjeh IM, de Sa DDC, Anavekar NS, Lahr BD, Sohail MR, Steckelberg JM, **Wilson WR**, Baddour LM. Incidence of infective endocarditis due to viridans group streptococci: impact of the 2007 American Heart Association's endocarditis prevention guidelines. *Cardiology*. 2012; 121(2):102.
112. Syed FF, Friedman P, Asirvatham S, Baddour L, Steckelberg J, Lohse C, **Wilson W**, Sohail M. Impact of device features and host characteristics on risk of pacemaker infection. *J Am Coll Cardiol*. 2013 Mar 12; 61(10):E287.
113. Palraj B, Baddour L, Steckelberg J, **Wilson W**, Sohail M. Validation of clinical criteria set to guide transesophageal echocardiography in the management of patients with staphylococcus aureus bacteremia. *J Am Coll Cardiol*. 2013 Mar 12; 61(10):E1084.
114. Nagpal A, Sohail MR, Espinosa RE, Friedman PA, Steckelberg JM, **Wilson WR**, Baddour LM. Effect on hospital length of stay for cardiovascular implantable electronic device infections following implementation of an evidence-based treatment algorithm. *Int J Antimicrob Agents*. 2013 May; 41:S15.
115. Palraj BR, Baddour LM, Steckelberg JM, **Wilson WR**, Sohail MR. Prevalence of endocarditis among patients with prosthetic heart valves and staphylococcus aureus bacteremia. *Int J Antimicrob Agents*. 2013 May; 41:S8.
116. Rangu V, Syed FF, Friedman PA, Baddour LM, Asirvatham SJ, Steckelberg JM, Lohse CM, **Wilson WR**, Sohail MR. Presence of a central venous catheter is associated with a markedly increased risk of permanent pacemaker infection. *Eur Heart J*. 2013 Aug; 34:660.
117. DeSimone DC, El Rafei A, Steckelberg J, Sohail M, **Wilson W**, Baddour L. Five-year mortality of infective endocarditis in a population-based cohort *Journal Of The American College Of Cardiology*. 2016 Apr 5; 67: (13)2184.
118. DeSimone DC, El Rafei A, Challener DW, Carr AB, Kelly JA, St Sauver JL, Lahr B, Steckelberg J, **Wilson W**, Baddour L. Impact of the American Heart Association's 2007 guidelines on the practice of dental prophylaxis for the prevention of infective endocarditis in high risk patients: Olmsted County, Minnesota *Journal Of The American College Of Cardiology*. 2016 Apr 5; 67: (13)2182.
119. Tan EM, Nagapl A, Desimone DC, Anderson B, Linderbaum J, De T, Li Z, Sohail MR, Cha YM, Loomis E, Espinosa R, Friedman PA, Greason K, Schiller H, Virk A, **Wilson WR**, Steckelberg JM, Baddour LM. Impact of a care process model on management of cardiovascular implantable electronic device infections *Open Forum Infectious Diseases* .2016;3:
120. Tan EM, Nagapl A, Desimone DC, Anderson B, Linderbaum J, De Ziel T, Li Z, Sohail MR, Cha YM, Loomis E, Espinosa R, Friedman PA, Greason K, Schiller H, Virk A, **Wilson WR**, Steckelberg JM, Baddour LM. Impact of a primary inpatient electrophysiology service on cardiovascular implantable electronic device infections in a tertiary care hospital *Open Forum Infectious Diseases*.2016;3:

121. Tan EM, Desimone DC, Sohail MR, Baddour LM, **Wilson WR**, Steckelberg JM, Virk A. Outcomes in patients with cardiovascular implantable electronic device infection managed with chronic antibiotic suppression Open Forum Infectious Diseases.2016;3:
122. El Rafei A, Desimone DC, Sohail MR, Steckelberg JM, **Wilson WR**, Baddour LM. Therapy for Enterococcus faecalis infective endocarditis in the era of a dual beta-lactam regimen: an institutional experience 2008-2015 Open Forum Infectious Diseases.2016;3:
123. Miranda W, Connolly H, Baddour L, Goel K, **Wilson W**, Greason K, Rihal C, Holmes D, Nkomo V, Ali M, Oh J, Pislaru S. Infective endocarditis following transcatheter aortic valve implantation: clinical, echocardiographic and hemodynamic features Journal Of The American College Of Cardiology. 2017 Mar 21; 69: (11)1960.
124. Sims J, Anavekar N, Chandrasekaran K, Steckelberg J, **Wilson W**, Gersh B, Baddour L, DeSimone D. Utility of cardiac computed tomography scanning in the diagnosis and pre-operative evaluation of patients with infective endocarditis Journal Of The American College Of Cardiology. 2017 Mar 21; 69: (11)1432.

Miscellaneous

1. **Wilson WR**. Symposium on infective endocarditis. Mayo Clin Proc. 1982 Jan; 57:3.
2. Taubert KA, **Wilson W**. Is endocarditis prophylaxis for dental procedures necessary? Heart Asia 2017; 9 (1):63-67 Epub 2017 Feb 23

* Indicates that the primary author was a mentee of this author.